WO1992001070A1 - High efficiency packaging of mutant adeno-associated virus using amber suppressions - Google Patents
High efficiency packaging of mutant adeno-associated virus using amber suppressions Download PDFInfo
- Publication number
- WO1992001070A1 WO1992001070A1 PCT/US1991/004765 US9104765W WO9201070A1 WO 1992001070 A1 WO1992001070 A1 WO 1992001070A1 US 9104765 W US9104765 W US 9104765W WO 9201070 A1 WO9201070 A1 WO 9201070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aav
- cells
- mutant
- amber
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- ADENO-ASSOCIATED VIRUS USING AMBER SUPPRESSION Described herein is the construction of an adenoassociated virus (AAV) plasmid containing an amber mutation within the AAV rep gene and the propagation of this mutant AAV on monkey cell lines containing an amber suppressor. It is shown that pure populations of AAV particles containing the mutant genome could be generated. The spontaneous reversion frequency of the amber mutation to wild-type was less tan 10 . This reversion frequency was significantly elevated by growth of the mutant virus in cultured human cells treated with mutagens. The amber mutant AAV particles provide a novel and sensitive assay for mutagenic agents in cultured human cells.
- AAV adenoassociated virus
- plasmids containing the entire adeno-associated virus genome are transfected into permissive cells infected with a helper adenovirus, infectious AAV particles are efficiently generated.
- These plasmids can be used to generate mutant AAV genomes or recombinant AAV vectors.
- Packaging of mutant AAV genomes has required complementation with a second AAV plasmid in the transfection assay which may lead to generation of significant amounts of wild-type AAV recombinants.
- One approach to alliviate production of wild-type recombinants was to generate conditional lethal mutants. We constructed an AAV-plasmid
- Sedivy et al. (Cell. 1987, 50:379) constructed monkey cell lines having an inducible human amber suppressor tRNA ser gene contained in an SV40 replicon. These cells also contain a temperaturesensitive SV40 T-antigen gene. Upon shift-down from non-permissive to permissive temperature, the
- suppressor tRNA gene is amplified allowing suppression of amber condons. These cells were used to propagate a poliovirus containing an amber mutation in its
- AAV2 adenoassociated virus type 2
- AAV2 genome cloned into recombinant bacterial plasmids is readily infectious.
- Transfection of recombinant AAV-plasmid DNA into adenovirus-infected cells results in efficient rescue of the AAV genome and replication free of plasmid to yield infectious AAV particles (Samulski et al., Proc. Natl. Acad. Sci. USA, 1982 79:2077; Laughlin et al., Gene, 1983, 23:65).
- In. vitro mutagenesis of recombinant AAV-plasmids has provided an approach to a genetic analysis of AAV
- Mutant AAV genomes or AAV vectors can be packaged into virus particles by complementation in the transfection assay but this often leads to generation of significant amounts of wild type genomes or low titers of the packaged mutant which may
- FIG. 1 Structure of the AAV genome and the amber mutation.
- the polyA site is at map position 96. RNAs from AAV promoters are shown as heavy arrows with the introns indicated by the caret. The coding regions for the four rep
- FIG. 2 Replication of the AAV amber mutant in the serine tRNA amber suppressor bearing cell lines.
- Control cell (SupO) or suppressor cell lines (SupD3 and SupD12) were infected with adenovirus and 1 hour later the different cell lines were transfected with pNTC244 containing the wild type AAV genome (w) or pNTC3 having the amber mutation (a) and incubated at 39.5oC or at 33oC. After appropriate incubation times the
- replicating viral DNA was isolated and analysed by agarose gel electrophoresis and Southern blotting using AAV2- 32 P-DNA. II and III indicate non-replicating DNA forms of input plasmid DNA.
- RFd, RFm and SS indicate replicating duplex dimer or monomer and single stranded forms respectively, of AAV DNA.
- M is molecular weight marker of linear duplex AAV2 DNA.
- FIG. 3 Replication of AAV amber mutant progeny in tRNA ser suppressor bearing cell lines.
- Viral lysates were prepared after transfecting amber mutant or wild type plasmid (as indicated at the top) into adenovirusinfected cell SupO, SupD3 and SupD12 cells (designed PO cells and marked 0, 3 and 12 respectively in the figure) and growing at 33oC or 39oC. These lysates were used to infect P1 cultures of SupO and SupD12 cells at 33oC.
- Viral DNA was isolated from the P1 cultures and analysed by agarose gel electrophoresis and Southern blotting with an AAV- 32 P-probe. The PO cultures were duplicates of those analysed in Figure 2.
- the letters a through 1 at the bottom of each track indicate the corresponding cultures in Figures 2 and 3.
- RFd, RFm and SS indicate the intracellular AAV
- M is molecular weight marker
- Figure 4 Reversion frequency of the amber mutation in pNTC3.
- Serial dilutions (10oto 10 -5 ) of the viral lysates of the amber AAV mutant (pNTC3 am) and the wild type AAV (pNTC244 wt) were used to infect adenovirusinfection viral DNA replicating forms were analysed.
- RFd, RFm and SS indicate intracellular AAV DNA species.
- M indicates a molecular weight marker of duplex AAV DNA.
- FIG. 5 Production of the rep proteins by the AAV rep amber mutant.
- Adenovirus-infected SupO and SupD12 cells were infected with 10 infectious units of wild type (wt) or amber mutant (am) viral lysates.
- Rep protein production was analysed by immunoblotting with an anti-rep antibody as described in Materials and Methods.
- Rep78, rep68, rep52 and rep40 indicate AAV2 rep
- Figure 6 Mutagen-induced reversion of the rep amber mutant AAV, NCT3.
- HelaJW cells (10 6 cells per 35 mm dish) growing at 37oC were infected either with the wild type virus, AAV wt or with the amber mutant virus, AAVam, each at a multiplicity of infection of 10 infectious units per cell as indicated. After two hours at 37oC the virus innoculum was removed and the cells were treated with mutagenic agents (indicated in figure) for 2 hours at 37oC. The mutagen was then removed and cells were infected with the helper
- adenovirus type 5 at a multiplicity of 3 plaque forming units per cell.
- the cells from each culture were harvested in a final volume of 0.2 ml.
- This viral lysate was frozen and thawed 3 times and heated at 65oC for 15 min.
- An aliquot (0.05 ml) of this virus lysate was used to infect 10 6 HelaJW cells (growing at.37oC in a 35 mm dish) together with helper adenovirus type 5 at a multiplicity of 3 plaque forming units per cell.
- AAV DNA was selectively extracted from the cultures and electrophoresed in a 0.7% agarose gel followed by blotting to a
- nitrocellulose membrane AAV DNA was detected by hybridization with an AAV 32 P-DNA probe followed by autoradiographic exposure to x-ray film.
- the mutagenic agents used were MNNG (N-methyl-N'-nitro-N-nitrosoguanidine) at 0.2 ⁇ g/ml (tracks 1,5) or 1.1 ⁇ g/ml (tracks 2,6); DMBA (7, 12-Dimethylbenz [a]- anthracene) at 0.4 ⁇ g/ml (tracks 3,7) or 2 ⁇ g/ml
- the invention provides a means of preparing
- the mutant virus was, in this instance, propagated in monkey cell lines expressing an amber suppressor gene. However, the method can be practiced using other cell lines containing the suppressor. The mutant could then be packaged without generation of wild type
- Monkey cells containing an inducible amber suppressor tRNA allow propagation and genetic analysis of AAV used herein.
- amber mutants While wild type particles may still be generated by reversion of the amber mutation, such spontaneous reversion occurred at low frequency.
- the preparations of amber mutants contained less that 1 in 10 5 wild type revertants. Since the particle to infectivity ratio for wild type AAV usually is about 20:1 to 50:1, the amber mutant described here can be used at relatively high multiplicity. The approach is, therefore useful for packaging other AAV mutants and AAV vectors in the absence of significant wild type recombinants.
- the invention can be used as an assay for effects of mutagenic agents in cultured human cells. Cultured human cells do not have
- any mutagenic agent which causes the amber mutation in the infecting AAV genome to revert to wild type or pseudowild type should allow expression of a functional AAV rep gene and thus the revertant virus would amplify and propagate.
- This provides a simple, novel and sensitive assay for analysis and detection of mutagenic agents by screening in cultured human cells. It is demonstrated that the reversion frequency of the mutant virus can be greatly increased by several orders of magnitude in a single growth cycle by known mutagenic agents. This provides a rapid and sensitive assay for mutagenic and potential genotoxic effects of compounds in human cells. Because AAV can grow in any type of human cells when infected with a helper adenovirus this mutagen assay will be applicable to any human cell lines.
- HelaJW cells Human Hela cells (HelaJW cells) were originally obtained from J. Janik (NIH) at passage 35 and were grown in monolayer cultures in Eagle's minimal
- the three monkey cell lines, BSCSupO, BSCSupD3 and BSCSupD12 (Sedivy et al., Cell, 1987, 50:379) were obtained at passage 3 from J. Sedivy and P. Sharp (MIT) . All three lines designated SupO, SupD3 and SupD12, respectively, were grown at 39.5oC in
- one 10 cm dish of confluent cells was split 1:4 into 6 cm or 1:12 into 3.5 cm dishes.
- the cultures were immediately placed at 33oC and the medium was changed after 24h. After an additional 24 h at 33oC the cells were infected with virus or
- the dishes with SupD3 or SupD12 cells contained about half the number of cells as the SupO cultures. This reflected
- the SupD12 cells are plated at 1:4 or 1:12 splits as above but grown overnight at 39.5oC or 72 h after infection or transfection at 33oC. The next day the cells are shifted to 33oC and 2 hr later infected with adenovirus and AAVam virus or transfected with pNTC3 DNA.
- Adeno-associated virus (AAV) type 2 and the human adenovirus type 5 (Ad) were grown as described (Carter et al., Virology, 1979, 92:449). Infectious titers of AAV were determined in the nuclear fluorescent-focus assay with indirect immunofluorescence using anti-AAV capsid rabbit antiserum and FITC-conjugated goat antirabbit IgG (Carter et al.. Virology, 1979, 92:449). Plasmids
- the plasmid pNTC244 contains a wild type AAV2 genome inserted in the polylinker sequence of the phagemid pTZ19U
- the mutant pNTC3 was constructed by using the synthetic oligonucleotide 5'-GATTACCTAGGAGAAGCAG-3' to introduce an amber codon into the AAV rep gene in pNTC244 as described further below.
- oligonucleotide was produced on an Associate Biosystem Model 381A synthesizer using B-cyanophosphoramidite chemistry and was subsequently purified by gel
- This mutant region was then reconstructed into a complete AAV genome in the plasmid pNTC244 to generate the mutant pNTC3.
- the presence of the appropriate mutation in the final AAV-plasmid recombinant, pNTC3 was again determined by DNA sequencing. Large scale amounts of the plasmid were then prepared for transfection assays.
- AAV DNA replication was analyzed using the modified Hirt SDS-high salt lysis procedure (Carter et al.,
- a stock of AAVam particles was prepared by transfection of pNTC3 into SupD12 cells in the presence of the helper
- the infectivity titer of the AAVam stock was determined as described above.
- HeLaJW cells (5 x10 5 cells per 35 mm dish grown at 37oC) were infected with the AAVam stock at a multiplicity of 10 infectious units per cell.
- the virus innoculum was allowed to absorb in a volume of 2 ml of complete medium (Eagle's minimal essential medium with 10% fetal calf serum and antibiotics) at 37oC for 2 hr.
- the innoculum was then removed, the cell monolayer was washed twice with 5 ml of complete medium then 2 ml of complete medium was added to the dish.
- the mutagenic agent was then added to the medium and the cells incubated for 2 hr at 37oC.
- MNNG N-methyl-N'-nitrosoguanidine
- DMBA 12-dimethylbenz[a]-anthracene
- BUdR 5-bromodeoxyuridine
- HU hydroxyurea
- BUdR was made as an aqueous stock solution at 400 ⁇ g/ml and added to 0.4 ⁇ g/ml or 2 ⁇ g/ml final concentration.
- HU was made as an aqueous solution at 100 mM and added to a final concentration of 1 mM. After incubation with the mutagens, the medium was removed, the cell monolayer was washed twice with medium and finally fresh medium (2 ml) was added to the dish. Adenovirus type 5 was then added to the cells at a multiplicity of 3 plaque forming units per cell and the cells were incubated at 37oC for 60 hr.
- the cells were then harvested from the dish, washed with 5 ml of phosphate buffered saline (PBS) then washed with 2 ml of medium and finally resuspended in 0.2 ml PBS.
- PBS phosphate buffered saline
- the cells were then frozen and thawed three times and heated at 65oC for 15 min. The debris was then removed by centrifuging and the supernatant was taken as the viral lysate. An aliquot (0.05 ml) of each lysate was used to infect fresh cultures of HeLaJW cells (5 x 10 5 cells per 35 mm dish) in the presence of adenovirus type 5 (3 plaque forming units per cell) . 40 hours after infection AAV DNA was selectively extracted and analyzed by gel electrophoresis, blotting,
- the agarose gel contained ethidium bromide to allow visualization of the DNA under UV light prior to blotting.
- the viral DNA from AAV wt infections and the high levels of revertants of AAVam induced by MNNG or DMBA could be directly seen in the ethidium bromide stained gel prior to blotting (data not shown) .
- AAV2 genome The structure of the AAV2 genome is shown in Fig. 1 (Srivastava et al., 1983).
- ORF2 large open reading frame
- VP1, VP2 and VP3 Two overlapping capsid polypeptides, VP1, VP2 and VP3 (Bacerra et al., J. Virol., 1988, 82:7919; Cassinnotti et al., Virology. 1988, 167:176; Trempe and Carter,
- ORF1 comprises the rep gene (Hermonat et al., J. Virol., 1984, 51:329; Tratschin et al., J . Virol., 1984, 51 :611) which may consist of the two overlapping genes.
- P 5 rep is transcribed from the p 5 promoter and yields two proteins, Rep78 and Rep68.
- P 19 rep is transcribed from the P 19 promoter and yields two proteins Rep52 and Rep40.
- the rep proteins are
- a nonsense mutation was introduced into ORF1 immediately upstream of the Bam-H1 site at map position 22 by converting a serine codon to the amber codon and reconstructing this into the wild type plasmid pNTC244 to yield the mutant pNTC3 (Fig. 1). If the amber mutation resulted in efficient translation termination it was expected to truncate all four rep proteins and yield a mutant that was rep. This mutant should be suppressed by the amber suppressor tRNA present in SupD3 and SupD12 cells. Since AAV2, like adenovirus and SV40, does not use the amber codon as a terminator for any genes it was not expected that the amber suppressor would interfere with normal growth of AAV. Growth of AAV on monkey cells.
- T-antigen which does not function for SV40 DNA replication but still provides the host-range helper function for adenovirus.
- All three cell lines SupO, SupD3 and SupD12 contain the SV40 tsA58 gene so should be permissive for AAV2 using the human adenovirus 5 as a helper. As shown in Table I, all three cell lines supported AAV growth at both 33oC and 39.5oC. The lower yield at 33oC probably reflects the slower growth rate at this temperature.
- SupD2 and SupD12 differ from SupO in having also an integrated human amber suppressor tRNA ser contained in an SV40 replicon (Sedivy et al., Cell. 1987, 50:379).
- the T- antigen expressed by the tsA58 gene becomes functional for SV40 DNA replication.
- Table I also show that expression of the amber suppressor was not inhibitory for growth of AAV.
- the mutant pNTC3 did not replicate in any of the cell lines at 39.5oC but the open circle (form II) or linearized (form III) species of the input plasmid DNA were seen.
- the open circle (form II) or linearized (form III) species of the input plasmid DNA were seen.
- replication of the mutant AAV genome from pNTC3 was readily detected in SupD12 cells and faintly on SupD3 cells but not in SupO cells.
- the amber mutation in the AAV rep gene of pNTC3 was only suppressed on SupD12 or SupD3 at 33oC.
- the SupD12 cells apparently suppressed the amber mutation more efficiently than did SupD3 cells (Fig. 2). This is consistent with evidence from Sedivy et al (1987) that, for a CAT gene containing an amber
- the level of suppression was 50 to 70% in SupD12 and about 20 to 30% in SupD3.
- the pNTC244 wild-type virus grown in PO cultures of all three cell lines yielded infectious AAV that replicated P1 cultures of both Sup0 and SupD12 and was not dependent upon amber suppression.
- the PO cultures of SupD3 or SupD12 transfected with pNTC3 yielded virus that replicated in P1 cultures of SupD12 cells but not in Sup0 cells.
- the PO cultures of Sup0 cells transfected with pNTC3 did not yield any infectious virus.
- Fig 3 showed that most of the virus particles generated by growth of pNTC3 on the amber suppressor cell lines (SupD3 and SupD12) at 33oC exhibited an amber mutant phenotype. However, this did not readily determine the level of reversion of the amber mutation.
- the immunofluorescence assay (Table 2) performed on Sup0 cells at 33oC showed a few cell nuclei that were positive for AAV capsid fluorescence when stocks of pNTC3 grown on SupD12 at 33oC were examined. Thus, some wild-type revertants apparently existed in the virus population. In contrast, no infectious virus were detected in lysates of Sup0 cells infected with pNTC3 (Table 2). However the immunofluorescence assay for AAV infectivity relies on the ability to detect the level at which 63% of the maximum number of nuclei are fluorescent for AAV capsid antigen.
- the actual titer of the revertants could not be determined readily because the number of fluorescent nuclei was too low and only the extreme end point of the titration was detected. Nevertheless, the titer of the pNTC3 derived virus grown on SupD12 cells was at least five orders of magnitude lower than that of the virus derived from pNTC244 (Table 2). This showed that the reversion frequency in pNTC3 stocks grown on SupD12 cells at 33oC was less than 10 -5 and probably less than 10 -6 .
- Rep proteins could not be easily detected in adenovirus- infected SupD12 or SupD3 cells after transfection at 33oC with pNTC3 although they could be detected after transfection with pNTC244 (data not shown). This reflected much lower expression of rep proteins after transfection with AAV plasmids than after AAV particlemediated infections. Also, the efficiency of
- Virus stocks containing wild-type or amber mutant genomes were generated from pNTC244 or pNTC3 respectively in SupD12 cells and used to infect SupD12 or Sup0 cells at 33oC. Wild-type AAV expressed similar amounts of the rep proteins in either cell line. The amber mutant expressed about 10 fold less amounts of both major rep proteins, rep78 and rep52 in SupD12 cells but not in Sup0 cells. These results showed that the amber suppressor did allow expression of rep proteins but at a lower overall efficiency than for wild type. Thus, the less efficient DNA replication and infectious virus production by the amber mutant was reflected in a lower level of rep protein synthesis.
- rep is
- the cap mutation can also be suppressed efficiently as for the rep gene to provide capsid proteins without generating a wild type cap gene.
- both classes of suppressible mutant genes may be used to supply AAV rep and/or cap gene functions under conditions in which infectious wild type AAV is not generated.
- These mutant rep or cap genes can be supplied as part of an AAV vector by a cotransfecting DNA molecule or as part of the infecting helper
- mutant genes can allow replication and packaging of AAV vectors (not containing a functional rep or cap gene) into AAV particles, under conditions where
- Vectors containing foreign genes or cDNA may be packaged into AAV particles by the method of the invention.
- Such vectors produced by the inventive techniques may be used to infect suitable cell cultures to produce high levels of proteins such as hormones, growth factors, enzymes or pharmacologically useful proteins.
- AAV vectors produced by the inventive means may be used to introduce genes or parts of genes into cells or patients for the purposes of diagnosing, alleviating or correcting genetic diseases or other diseases.
- the inventive procedure produces pure populations of mutant virus which may be used as the basis of an assay for mutagenesis in cultured human cells and thus for screening potential mutagenic and carcinogenic agents. Such agents may be tested by their effect on the reversion frequency of the mutant virus.
- the invention of the mutant AAV provides a novel assay for screening mutagenicity of compounds in human (or other mammalian) cells.
- mutagenesis have been proposed previously for use in mammalian cells but many of these use shuttle vectors to measure the "forward" mutation rate of an active gene from a wild type to a mutant phenotype.
- the spontaneous rate of such mutations is frequently prohibitively high to readily measure the specific effect of mutagens in inducing such forward mutations.
- Mutagenicity of any agent may be evaluated by any method which provides for growth of a cell line which has been infected with a virus containing an amber mutation in an essential AAV gene in the presence of a putative genotoxic agent.
- the mutagenicity of the putative genotoxic agent is evidenced by increased incidence of wild type or pseudo wild type virus, as measured by viral DNA or proteins.
- the mutant virus can be infected into cells of any human or other mammalian tissue eg. liver, lung.
- wild type (and thus revertant) AAV will grow in any human cells from any tissue provided a helper adenovirus is present (Carter, Handbook of Parvoviruses Vol. 1, CRC Press, 1989 pp 255-282).
- the invention will be useful for analysing mutagenic effects of compounds whose
- mutagenic or genotoxic effect is actually mediated by an intermediate metabolite which is generated by tissue specific enzymes.
- tissue specific enzymes most shuttle vectors previously designed for mutagenesis assays in mammalian cells are restricted in their replication to specific types of cells or even specific host.
- one mutagenic event per 10 6 cells treated with mutagen can yield 10 4 infectious units.
- rep and capsid proteins are clearly defined and specific antibodies have been developed (Mendelson et al., J. Virology 1986, 60:823; Trempe et al., Virology 1987, 161:18; Carter et al., Virology
- a fourth novel feature of the present invention is that the AAV genome in the infecting particle is single-stranded DNA. All other shuttle vectors or mammalian viruses suggested for mutagenesis assays have double stranded DNA genomes. Because the infecting AAVam genome is single-stranded (prior to conversion to the first double strand intermediate by host cell enzymes) it offers a unique type of target which may detect additional mutagenic events more readily than with double stranded genomes.
- helper virus eg. adenovirus
- E. coli. containing the plasmid pNTC3 has been deposited in the American Type Culture Collection in Rockville, Maryland under the provisions of the
- accession number is 68000 and was received on June 1, 1989.
- the AAV virus titer was determined using the fluorescent focus assay (Carter et al., Virology, 1979, 92:449) on Hela cells. Table 2
- AAV2 (pNTC244) SupD12 4.0 ⁇ 10 8 1.5 ⁇ 10 8
- AAV2 (pNTC244) Sup0 3.2 ⁇ 10 8 1.4 ⁇ 10 8
- AAV2 (pNTC3) SupD12 4.0 ⁇ 10 7 ⁇ 1.0 ⁇ 10 3
- AAV2 (pNTC3) Sup0 0 0a Virus stocks were prepared by transfecting 1 ⁇ g of the indicated plasmid onto SupD12 or Sup0 cell at 33oC. Lysates were prepared at 90 hr after
- Titers are expressed as AAV2 infectious units per ml.
Abstract
Described is the construction of an adeno-associated virus (AAV) plasmid containing an amber mutation within the AAV rep gene and the propagation of this mutant AAV on monkey cell lines containing an amber suppressor. It is shown that pure populations of AAV particles containing the mutant genome could be generated. The spontaneous reversion frequency of the amber mutation to wild-type was less than 10-5. This reversion frequency was significantly elevated by growth of the mutant virus in cultured human cells treated with mutagens. The amber mutant AAV particles provide a novel and sensitive assay for mutagenic agents in cultured human cells.
Description
HIGH EFFICIENCY PACKAGING OF MUTANT
ADENO-ASSOCIATED VIRUS USING AMBER SUPPRESSION Described herein is the construction of an adenoassociated virus (AAV) plasmid containing an amber mutation within the AAV rep gene and the propagation of this mutant AAV on monkey cell lines containing an amber suppressor. It is shown that pure populations of AAV particles containing the mutant genome could be generated. The spontaneous reversion frequency of the amber mutation to wild-type was less tan 10 . This reversion frequency was significantly elevated by growth of the mutant virus in cultured human cells treated with mutagens. The amber mutant AAV particles provide a novel and sensitive assay for mutagenic agents in cultured human cells.
SUMMARY OF THE INVENTION
When recombinant plasmids containing the entire adeno-associated virus genome are transfected into permissive cells infected with a helper adenovirus, infectious AAV particles are efficiently generated. These plasmids can be used to generate mutant AAV genomes or recombinant AAV vectors. Packaging of mutant AAV genomes has required complementation with a second AAV plasmid in the transfection assay which may lead to generation of significant amounts of wild-type AAV recombinants. One approach to alliviate production of wild-type recombinants was to generate conditional lethal mutants. We constructed an AAV-plasmid
recombinant having a nonsense mutation in the AAV rep gene by using oligonucleotide-directed mutagenesis to convert a serine codon to an amber codon. We show that this mutant AAV can be grown on monkey cell lines containing an inducible human serine tRNA amber
suppressor. The amber suppression is efficient and yields a burst of mutant AAV particles at about 10% of the titer of wild type AAV. Subsequent infection of non-suppressor cells with the mutant AAV showed that the spontaneous reversion frequency of the amber mutation was less than 10-5. This reversion frequency was significantly enhanced by growth of the mutant virus in cultured human cells treated with mutagens. This provides a novel and sensitive assay to analyse mutagenic agents in human cells.
BACKGROUND OF THE INVENTION
Genetic analysis in many systems has been greatly advanced by the exploitation of conditional-lethal mutations such as temperature-sensitivity or host-range dependence. Also suppression of nonsense mutations by suppressor tRNAs has been very important in prokaryotes and lower eukaryotes.
Recently, Sedivy et al., (Cell. 1987, 50:379) constructed monkey cell lines having an inducible human amber suppressor tRNAser gene contained in an SV40 replicon. These cells also contain a temperaturesensitive SV40 T-antigen gene. Upon shift-down from non-permissive to permissive temperature, the
suppressor tRNA gene is amplified allowing suppression of amber condons. These cells were used to propagate a poliovirus containing an amber mutation in its
replicase gene. We have examined the use of these cell lines for propagation of amber mutation of adenoassociated virus type 2 (AAV2).
The AAV2 genome cloned into recombinant bacterial plasmids is readily infectious. Transfection of recombinant AAV-plasmid DNA into adenovirus-infected
cells results in efficient rescue of the AAV genome and replication free of plasmid to yield infectious AAV particles (Samulski et al., Proc. Natl. Acad. Sci. USA, 1982 79:2077; Laughlin et al., Gene, 1983, 23:65). In. vitro mutagenesis of recombinant AAV-plasmids has provided an approach to a genetic analysis of AAV
(Tratschin et al., J. Virol., 1984, 51:611; Hermonat et al., J. Virol., 1984, 51:329 and to generation of AAV vectors for introduction and expression of foreign genes in mammalian cells (Hermonat and Muzyczka, Proc. Natl. Acad. Sci. USA. 1984, 81:6466; Tratschin et al., Mol. cell. Biol., 1984, 4:2072 and 1985, 5:3251;
McLaughlin et al., J. Virol., 1988, 62:1963; Lebkowski et al., Mol. Cell. Biol., 1988 8:3998). This genetic analysis requires introduction of mutant genomes via DNA transfection which may have physiological
differences to normal viral growth following infection with AAV particles. Mutant AAV genomes or AAV vectors can be packaged into virus particles by complementation in the transfection assay but this often leads to generation of significant amounts of wild type genomes or low titers of the packaged mutant which may
complicate both genetic analysis and certain other uses of AAV vectors.
A significant obstacle in studies on AAV and the development of AAV vectors has been the difficulty in generating high titer stocks of particles containing defined mutant genomes or AAV vectors free of wild type contamination. The generation of recombinant plasmids containing the entire AAV genome (Samulski et al.,
Proc. Natl. Acad. Sci. USA., 1982, 79:2077; Laughlin et al., Gene, 1983 23:65) facilitated construction of
defined mutants or vectors which could be analyzed by DNA transfection of permissive cells (Hermonat et al., J. Virol.. 1984, 57:329; Tratschin et al., J. Virol.,
1984, 51:611). However, this leads to uncertainties concerning the accuracy with which events after DNA transfection reflect those events which occur in a normal infection with AAV particles. The mutant AAV genomes from plasmids can be packaged into AAV
particles by cotransfection with appropriate
complementing plasmids expressing the AAV rep or cap genes (Hermonat and Muzyczka, Proc. Natl. Acad. Sci. USA, 1984, 81:6466; Tratschin et al., Mol. Cell. Biol.,
1985, 5:3251; Lebkowski et al., Mol. Cell. Biol., 1988, 8: 3988; McLaughlin et al., J. Virol., 1988 62:1963). However, the titer of such mutant particle preparations was generally low. In addition significant levels of wild type recombinants were often generated even when there was no direct AAV DNA sequence homology between the complementing AAV plasmids (Senapathy and Carter, J. Biol. Chem., 1984, 259:4661). The presence of the wild type recombinants has prevented efficient genetic analysis of AAV via particle-mediated transfections and has compromised the efficient use of AAV vectors. For AAV vectors packaged into transdusing particles the presence of wild type genomes is an additional problem because of the strong negative regulatory effect of rep on expression in many cell types (Tratschin et al.,
Mol. Cell. Biol., 1986, 6:2884; Lebow et al., Mol.
Cell. Biol.. 1987, 2:1320; McLaughlin et al., J.
Virol. , 1988, 62: 1963; Mendelson et al., Virology, 1988, 166:612).
One approach to these problems is to generate conditional lethal mutations in an essential AAV gene. It was an object of the present invention to construct an amber mutation in the AAV rep gene to generate a conditional lethal mutant AAV that can grow in cell lines containing an amber suppressor gene.
FIGURE LEGENDS
Figure 1 Structure of the AAV genome and the amber mutation. The AAV2 genome is shown as a single bar with 100 map units scale (1 unit = approximately 47 nucleotides). Stippled boxes indicate terminal repeats (replication origins) and solid circles indicate transcription promoters, (p5, p19 and p40) . The polyA site is at map position 96. RNAs from AAV promoters are shown as heavy arrows with the introns indicated by the caret. The coding regions for the four rep
proteins (rep78, rep68, rep52 and rep40) and for the viral capsids (VP1, VP2 and VP3) are shown with open boxes. The lower portion shows the extended region of the AAV genome where the amber codon was generated by site-directed mutagenesis.
Figure 2 Replication of the AAV amber mutant in the serine tRNA amber suppressor bearing cell lines. Control cell (SupO) or suppressor cell lines (SupD3 and SupD12) were infected with adenovirus and 1 hour later the different cell lines were transfected with pNTC244 containing the wild type AAV genome (w) or pNTC3 having the amber mutation (a) and incubated at 39.5ºC or at 33ºC. After appropriate incubation times the
replicating viral DNA was isolated and analysed by agarose gel electrophoresis and Southern blotting using AAV2-32P-DNA. II and III indicate non-replicating DNA
forms of input plasmid DNA. RFd, RFm and SS indicate replicating duplex dimer or monomer and single stranded forms respectively, of AAV DNA. M is molecular weight marker of linear duplex AAV2 DNA.
Figure 3 Replication of AAV amber mutant progeny in tRNAser suppressor bearing cell lines. Viral lysates were prepared after transfecting amber mutant or wild type plasmid (as indicated at the top) into adenovirusinfected cell SupO, SupD3 and SupD12 cells (designed PO cells and marked 0, 3 and 12 respectively in the figure) and growing at 33ºC or 39ºC. These lysates were used to infect P1 cultures of SupO and SupD12 cells at 33ºC. Viral DNA was isolated from the P1 cultures and analysed by agarose gel electrophoresis and Southern blotting with an AAV-32P-probe. The PO cultures were duplicates of those analysed in Figure 2. The letters a through 1 at the bottom of each track indicate the corresponding cultures in Figures 2 and 3. RFd, RFm and SS indicate the intracellular AAV
molecules. M, is molecular weight marker.
Figure 4 Reversion frequency of the amber mutation in pNTC3. Serial dilutions (10ºto 10-5) of the viral lysates of the amber AAV mutant (pNTC3 am) and the wild type AAV (pNTC244 wt) were used to infect adenovirusinfection viral DNA replicating forms were analysed.
RFd, RFm and SS indicate intracellular AAV DNA species. M indicates a molecular weight marker of duplex AAV DNA.
Figure 5 Production of the rep proteins by the AAV rep amber mutant. Adenovirus-infected SupO and SupD12 cells were infected with 10 infectious units of wild type (wt) or amber mutant (am) viral lysates. Rep
protein production was analysed by immunoblotting with an anti-rep antibody as described in Materials and Methods. Ad - adenovirus-infected control cell.
Rep78, rep68, rep52 and rep40 indicate AAV2 rep
proteins.
Figure 6 Mutagen-induced reversion of the rep amber mutant AAV, NCT3. HelaJW cells (106 cells per 35 mm dish) growing at 37ºC were infected either with the wild type virus, AAV wt or with the amber mutant virus, AAVam, each at a multiplicity of infection of 10 infectious units per cell as indicated. After two hours at 37ºC the virus innoculum was removed and the cells were treated with mutagenic agents (indicated in figure) for 2 hours at 37ºC. The mutagen was then removed and cells were infected with the helper
adenovirus type 5 at a multiplicity of 3 plaque forming units per cell. After 60 hours at 37ºC the cells from each culture were harvested in a final volume of 0.2 ml. This viral lysate was frozen and thawed 3 times and heated at 65ºC for 15 min. An aliquot (0.05 ml) of this virus lysate was used to infect 106 HelaJW cells (growing at.37ºC in a 35 mm dish) together with helper adenovirus type 5 at a multiplicity of 3 plaque forming units per cell. 40 hours later AAV DNA was selectively extracted from the cultures and electrophoresed in a 0.7% agarose gel followed by blotting to a
nitrocellulose membrane. AAV DNA was detected by hybridization with an AAV 32P-DNA probe followed by autoradiographic exposure to x-ray film. The mutagenic agents used were MNNG (N-methyl-N'-nitro-N-nitrosoguanidine) at 0.2 μg/ml (tracks 1,5) or 1.1 μg/ml (tracks 2,6); DMBA (7, 12-Dimethylbenz [a]-
anthracene) at 0.4 μg/ml (tracks 3,7) or 2 μg/ml
(tracks 4,8); HU (hydroxyurea) at 1mM (tracks 11,15); BUdr (5-bromodeoxyuridine) at 0.4 μg/ml (tracks 12,16) or 2 μg/ml (tracks 13,17). Controls included: Ad, lysates from cells infected with adenovirus alone, (track 9) ; C, lysates from uninfected cells, (track 10) ; D, lysates from cells infected with AAV wt (track 14) or AAVam (track 18) and treated with
dimethylsulfoxide (final concentration 2% v/v)
DETAILED DESCRIPTION OF THE INVENTION
The invention provides a means of preparing
conditional-lethal nonsense mutants of AAV by
inactivating the rep gene using an amber mutation. The mutant virus was, in this instance, propagated in monkey cell lines expressing an amber suppressor gene. However, the method can be practiced using other cell lines containing the suppressor. The mutant could then be packaged without generation of wild type
recombinants directly. Monkey cells containing an inducible amber suppressor tRNA allow propagation and genetic analysis of AAV used herein. However,
functional equivalents may be used by the method of the invention
While wild type particles may still be generated by reversion of the amber mutation, such spontaneous reversion occurred at low frequency. The preparations of amber mutants contained less that 1 in 105 wild type revertants. Since the particle to infectivity ratio for wild type AAV usually is about 20:1 to 50:1, the amber mutant described here can be used at relatively high multiplicity. The approach is, therefore useful for packaging other AAV mutants and AAV vectors in the
absence of significant wild type recombinants.
Because the spontaneous reversion frequency of the mutant virus is very low the invention can be used as an assay for effects of mutagenic agents in cultured human cells. Cultured human cells do not have
naturally occurring amber suppressor genes and thus the mutant AAV cannot grow in such cells even when
coinfected with a helper adenovirus. However any mutagenic agent which causes the amber mutation in the infecting AAV genome to revert to wild type or pseudowild type should allow expression of a functional AAV rep gene and thus the revertant virus would amplify and propagate. This provides a simple, novel and sensitive assay for analysis and detection of mutagenic agents by screening in cultured human cells. It is demonstrated that the reversion frequency of the mutant virus can be greatly increased by several orders of magnitude in a single growth cycle by known mutagenic agents. This provides a rapid and sensitive assay for mutagenic and potential genotoxic effects of compounds in human cells. Because AAV can grow in any type of human cells when infected with a helper adenovirus this mutagen assay will be applicable to any human cell lines.
Cells
Human Hela cells (HelaJW cells) were originally obtained from J. Janik (NIH) at passage 35 and were grown in monolayer cultures in Eagle's minimal
essential medium supplemented with 10% fetal calf serum in 5% C02.
The three monkey cell lines, BSCSupO, BSCSupD3 and BSCSupD12 (Sedivy et al., Cell, 1987, 50:379) were obtained at passage 3 from J. Sedivy and P. Sharp
(MIT) . All three lines designated SupO, SupD3 and SupD12, respectively, were grown at 39.5ºC in
Dulbecco's modified Eagle's medium with 10% fetal calf serum in 5% C02 in 10 cm dishes. For routine passage the cells were split 1:50 about every six days. The antibiotic geneticin (700 μ/ml total concentration) was included in the medium in alternate passages and care was taken to avoid exposure of the cell cultures to temperatures below 39.5ºC.
For experiments, one 10 cm dish of confluent cells was split 1:4 into 6 cm or 1:12 into 3.5 cm dishes. The cultures were immediately placed at 33ºC and the medium was changed after 24h. After an additional 24 h at 33ºC the cells were infected with virus or
transfected with DNA. Under these conditions, at the time of infection or transfection, the dishes with SupD3 or SupD12 cells contained about half the number of cells as the SupO cultures. This reflected
induction of the suppressor tRNA in SupD3 and SupD12. Parallel control cultures were maintained at 39.5ºC. After 24 h at 39.5ºC these cultures were refed with fresh (prewarmed) medium, then infected with virus or transfected with DNA 4 h later.
In more recent experiments for propagation of the AAVam mutant, NTC3, the SupD12 cells are plated at 1:4 or 1:12 splits as above but grown overnight at 39.5ºC or 72 h after infection or transfection at 33ºC. The next day the cells are shifted to 33ºC and 2 hr later infected with adenovirus and AAVam virus or transfected with pNTC3 DNA.
For analysis of AAV DNA replication, 39.5ºC
cultures were harvested at 24 h after virus infection
or 40 h after DNA transfection and 33ºC cultures were harvested at 40 h after infection or 70 h after
transfection. For assay of viral proteins or
infectious progeny virus, cells were harvested at 48 h after infection or transfection at 39.5ºC. Viral lysates from transfected cultures were concentrated ten fold. The choice of harvesting times reflects the two-fold decrease in the AAV growth rate at 33ºC (Myers et al., J. Virol., 1980, 35:65) and the less efficient growth in transfected cultures (Laughlin et al., Gene, 1983, 23:65; Tratschin et al., J. Virol., 1984,
51:619).
Human HeLa cells were grown at 37ºC in Eagle's minimal essential medium with 10% fetal calf serum. DNA transfection
Cells were plated as described above and
transfected with the appropriate plasmid according to the CaPO4 precipitation procedure (Tratschin et al., Mol. Cell. Biol., 1984, 4:2072). When required for AAV replication, the cells were infected with adenovirus type 5 at a multiplicity of infection of 3 to 5
infectious units per cell one hour prior to DNA
transfection.
Virus growth and infectivity assay.
Adeno-associated virus (AAV) type 2 and the human adenovirus type 5 (Ad) were grown as described (Carter et al., Virology, 1979, 92:449). Infectious titers of AAV were determined in the nuclear fluorescent-focus assay with indirect immunofluorescence using anti-AAV capsid rabbit antiserum and FITC-conjugated goat antirabbit IgG (Carter et al.. Virology, 1979, 92:449).
Plasmids
Stocks of plasmids were grown in E. coli and purified by standard procedures (Maniatis et al.,
"Molecular Cloning" 1982, Laughlin et al., Gene, 1983, 23:65; Tratschin et al., J. Virol., 1984, 51:619). All plasmid preparations used for transfection or DNA sequencing were twice banded in CsCl. The plasmid pNTC244 contains a wild type AAV2 genome inserted in the polylinker sequence of the phagemid pTZ19U
(Chejanovsky and Carter, Virology. 1989, 173:120).
Construction of mutants
The mutant pNTC3 was constructed by using the synthetic oligonucleotide 5'-GATTACCTAGGAGAAGCAG-3' to introduce an amber codon into the AAV rep gene in pNTC244 as described further below. The
oligonucleotide was produced on an Associate Biosystem Model 381A synthesizer using B-cyanophosphoramidite chemistry and was subsequently purified by gel
electrophoresis. The oligonucleotide was then
constructed into the pNTC244 background according to the general procedures of Zoller and Smith Methods in Enzvmology, 1983, 100:468 and Kunkel Proc. Natl. Acad. Sci. USA., 1985, 82.:448 as implemented in the BioRad Muta-gene system (BioRad Laboratories, Richmond, CA) . Briefly, the synthetic oligonucleotide was used to prime a DNA polymerase reaction with a single-stranded template consisting of an M13 vector containing an insert of a sub-genomic portion (nucleotides 449 to 1045) of the AAV genome. Plaques containing the mutations were selected and the successful generation of the nutation was checked by DNA sequencing. This mutant region was then reconstructed into a complete
AAV genome in the plasmid pNTC244 to generate the mutant pNTC3. The presence of the appropriate mutation in the final AAV-plasmid recombinant, pNTC3 was again determined by DNA sequencing. Large scale amounts of the plasmid were then prepared for transfection assays.
Sequencing was performed using the
dideoxynucleotide procedure, [-35S]-labeled nucleotides, and the mutant T7 DNA polymerase, sequenase (United States Biochemical Corporation) on either single-stranded phagemid or double-stranded plasmid templates. Analysis of viral DNA replication.
AAV DNA replication was analyzed using the modified Hirt SDS-high salt lysis procedure (Carter et al.,
Viroloy. 1983, 126:505) to extract viral-specific DNA. This DNA was electrophoresed in 0.7% agarose gels (11 x 14 cm) for 16 hr at 10 mA/gel and blotted to
nitrocellulose followed by hybridization with AAV 32P-DNA labeled in vitro by random priming (Feinberg and Vogelstein, Anal. Biochem., 1982, 132:6).
Analysis of AAV protein synthesis.
Synthesis of AAV rep proteins (Rep78, Rep68, Rep52 and Rep40) was determined using specific antisera in immunoblotting assays (Medelson et al., J. Virol.,
1986, 60:823) using a rabbit antiserum (anti rep78.93) raised against a 93% region of rep78 expressed from a prokaryotic vector in E. coli (Trempe et al., Virology,
1987, 161:18)
Assay of reversion induced bv mutagenic agents.
The ability of mutagenic agents to induce reversion of the amber mutation in NTC3 to wild type or pseudowild type was tested using HeLaJW cells. A stock of AAVam particles was prepared by transfection of pNTC3
into SupD12 cells in the presence of the helper
adenovirus and growth at 33ºC as described above. The infectivity titer of the AAVam stock was determined as described above.
To determine the effect of mutagens HeLaJW cells (5 x105 cells per 35 mm dish grown at 37ºC) were infected with the AAVam stock at a multiplicity of 10 infectious units per cell. The virus innoculum was allowed to absorb in a volume of 2 ml of complete medium (Eagle's minimal essential medium with 10% fetal calf serum and antibiotics) at 37ºC for 2 hr. The innoculum was then removed, the cell monolayer was washed twice with 5 ml of complete medium then 2 ml of complete medium was added to the dish. The mutagenic agent was then added to the medium and the cells incubated for 2 hr at 37ºC. The mutagenic agents used were: MNNG (N-methyl-N'-nitrosoguanidine) obtained from Sigma Chemical Company, St. Louis, MO; DMBA (7, 12-dimethylbenz[a]-anthracene) obtained from Aldrich Chemical Company, Milwaukee, WI; BUdR (5-bromodeoxyuridine) and HU (hydroxyurea)both obtained from Calbiochem. MNNG and DMBA were prepared as stock solution at 400 μg/ml in DMSO
(dimethylsulfoxide) and added to the cell medium to give final concentration of 0.22 μg/ml or 1:1 μg/ml (MNNG) or 0.4 μg/ml and 2 μg/ml DMBA. Controls
included cells treated with DMSO alone at final a concentration of 2% (v/v) . BUdR was made as an aqueous stock solution at 400 μg/ml and added to 0.4 μg/ml or 2 μg/ml final concentration. HU was made as an aqueous solution at 100 mM and added to a final concentration of 1 mM.
After incubation with the mutagens, the medium was removed, the cell monolayer was washed twice with medium and finally fresh medium (2 ml) was added to the dish. Adenovirus type 5 was then added to the cells at a multiplicity of 3 plaque forming units per cell and the cells were incubated at 37ºC for 60 hr. The cells were then harvested from the dish, washed with 5 ml of phosphate buffered saline (PBS) then washed with 2 ml of medium and finally resuspended in 0.2 ml PBS. The cells were then frozen and thawed three times and heated at 65ºC for 15 min. The debris was then removed by centrifuging and the supernatant was taken as the viral lysate. An aliquot (0.05 ml) of each lysate was used to infect fresh cultures of HeLaJW cells (5 x 105 cells per 35 mm dish) in the presence of adenovirus type 5 (3 plaque forming units per cell) . 40 hours after infection AAV DNA was selectively extracted and analyzed by gel electrophoresis, blotting,
hybridization with an AAV32P-DNA probe and
autoradiography as described above. The agarose gel contained ethidium bromide to allow visualization of the DNA under UV light prior to blotting. The viral DNA from AAV wt infections and the high levels of revertants of AAVam induced by MNNG or DMBA could be directly seen in the ethidium bromide stained gel prior to blotting (data not shown) .
RESULTS AAV genome structure and construction of a Rep amber mutant.
The structure of the AAV2 genome is shown in Fig. 1 (Srivastava et al., 1983). In the right half of the genome a large open reading frame (ORF2) is expressed
from RNA transcribed from the p40 promoter and codes for three overlapping capsid polypeptides, VP1, VP2 and VP3 (Bacerra et al., J. Virol., 1988, 82:7919; Cassinnotti et al., Virology. 1988, 167:176; Trempe and Carter,
Virology, 1988, (62: 3356). In the left half of the genome, a large open frame ORF1 yields four overlapping rep proteins (Mendelson et al., J. Virol., 1986,
60:823). Thus, ORF1 comprises the rep gene (Hermonat et al., J. Virol., 1984, 51:329; Tratschin et al., J . Virol., 1984, 51 :611) which may consist of the two overlapping genes. P5 rep is transcribed from the p5 promoter and yields two proteins, Rep78 and Rep68. P19 rep is transcribed from the P19 promoter and yields two proteins Rep52 and Rep40. The rep proteins are
required for AAV DNA replication and also mediate positive and negative trans-acting pleiotropic effects on genes expressed from AAV or heterologous viral and cellular promoters (Tratschin et al., Mol. Cell. Biol., 1986, 6:2884; Labow et al., J. Virol., 1986, 60:251 and Mol. Cell. Biol., 1989, 7:1320; Mendelson et al.,
Virology, 1988, 166:612; Trempe and Carter, J. Virol., 1988, 62.:68).
A nonsense mutation was introduced into ORF1 immediately upstream of the Bam-H1 site at map position 22 by converting a serine codon to the amber codon and reconstructing this into the wild type plasmid pNTC244 to yield the mutant pNTC3 (Fig. 1). If the amber mutation resulted in efficient translation termination it was expected to truncate all four rep proteins and yield a mutant that was rep. This mutant should be suppressed by the amber suppressor tRNA present in SupD3 and SupD12 cells. Since AAV2, like adenovirus
and SV40, does not use the amber codon as a terminator for any genes it was not expected that the amber suppressor would interfere with normal growth of AAV. Growth of AAV on monkey cells.
Monkey cell lines show varying degrees of
permissiveness for replication of human adenovirus (Rabson et al., Proc. Soc. Exptl., Biol. Med., 1964, 116:187; Rice and Klessig, J. Virol., 1984, 49:35) due to inefficient expression of adenovirus late proteins. Monkey cells express a similar host range restriction for expression of AAV2 capsid proteins when using a human adenovirus as helper (Buller et al., J. Gen.
Virol., 1979, 40:241). For both AAV and adenovirus this host range restriction may be alleviated by coinfection with SV40 (Rabson et al., 1964; Buller et al., 1979). The host range helper function is mediated by SV40 T-antigen and requires only the carboxylterminal region of the T-antigen. Thus, a mutant SV40, tsA58, containing a temperature sensitive lesion
(Tegtmeyer and Ozer, J. Virol.. 1971, 8:516) expresses a T-antigen which does not function for SV40 DNA replication but still provides the host-range helper function for adenovirus.
All three cell lines SupO, SupD3 and SupD12 contain the SV40 tsA58 gene so should be permissive for AAV2 using the human adenovirus 5 as a helper. As shown in Table I, all three cell lines supported AAV growth at both 33ºC and 39.5ºC. The lower yield at 33ºC probably reflects the slower growth rate at this temperature.
SupD2 and SupD12 differ from SupO in having also an integrated human amber suppressor tRNAser contained in an SV40 replicon (Sedivy et al., Cell. 1987, 50:379).
Upon downshift of cells from 39.5ºC to 33ºC, the T- antigen expressed by the tsA58 gene becomes functional for SV40 DNA replication. This leads to amplification of the SV40 replicon containing the amber suppressor and provides a greatly increased copy number and high expression of the suppressor tRNA which in turn allows efficient amber suppression. Thus, the data in Table I also show that expression of the amber suppressor was not inhibitory for growth of AAV.
Suppression of the AAV rep gene nonsense mutation in SUPD3 and SUPD12 cells.
Results of examination of suppression of the nonsense mutation in AAV2 by transfection of the pNTC3 or pNTC244 DNA into adenovirus-infected cells and subsequent analysis of the intracellular AAV DNA by gel electrophoresis can be seen in Figure 2. At 39.5ºC or 33.0ºC, the wild-type plasmid, pNTC244, showed AAV intracellular DNA species expected for normal AAV DNA replication. The wild-type plasmid replicated less well at 33º C than at 39.5ºC which may reflect the slower growth rate of the cells at the lower
temperature. The mutant pNTC3 did not replicate in any of the cell lines at 39.5ºC but the open circle (form II) or linearized (form III) species of the input plasmid DNA were seen. At 33ºC, replication of the mutant AAV genome from pNTC3 was readily detected in SupD12 cells and faintly on SupD3 cells but not in SupO cells. Thus, the amber mutation in the AAV rep gene of pNTC3 was only suppressed on SupD12 or SupD3 at 33ºC. The SupD12 cells apparently suppressed the amber mutation more efficiently than did SupD3 cells (Fig. 2). This is consistent with evidence from Sedivy et al
(1987) that, for a CAT gene containing an amber
mutation, the level of suppression was 50 to 70% in SupD12 and about 20 to 30% in SupD3.
Suppression of the nonsense mutation in PNTC3 yielded viral particles containing mutant AAV genomes.
It was conceivable that the replication of pNTC3 in SupD3 or SupD12 cells at 33ºC simply reflected a high frequency of reversion of the nonsense mutation in these cells rather than suppression by the induced suppressor tRNAser. To test this, a set of cell culture (PO cultures) which were duplicates of those described in Figure 2, were harvested for preparation of virus lysates. Aliquots of these lysates were then used to infect Sup0 or SupD12 cells (P1 cultures) in the presence of adenovirus at 33ºC. Viral DNA was
extracted and analysed by agarose gel electrophoresis as shown in Fig 3. The presence of replicating AAV DNA in the P1 cultures is diagnostic of infectious AAV particles in the PO lysates.
As can be seen in Fig 3, the pNTC244 wild-type virus grown in PO cultures of all three cell lines yielded infectious AAV that replicated P1 cultures of both Sup0 and SupD12 and was not dependent upon amber suppression. In contrast, the PO cultures of SupD3 or SupD12 transfected with pNTC3 yielded virus that replicated in P1 cultures of SupD12 cells but not in Sup0 cells. The PO cultures of Sup0 cells transfected with pNTC3 did not yield any infectious virus.
The results in Figure 3 are consistent with those of Figure 2. Together they show that the bulk of the infectious AAV virus produced by transfection of SupD3 or SupD12 cells with pNTC3 retained its amber mutant
phenotype.
In the experiment of Fig 3, comparison of the relative amounts of RF DNA suggested that the yield of infectious mutant virus from the PO SupD3 cells was less than from the SupD12 cells. This is consistent also with the less efficient amber suppression on SupD3 cells observed in Fig 2. For subsequent experiments we used only the SupD12 cells as the permissive host for pNTC3.
Efficiency of suppression of pNTC3 on SupD12 cells.
To measure the relative efficiency of amber
suppression, pNTC244 and pNTC3 were grown on both
SupD12 and Sup0 cells at 33ºC, then assayed for
infectivity of the resulting virus stocks on SupD12 cells at 33ºC. The plasmid pNTC244 gave an efficient yield of virus when grown on either cell line. pNTC3 yielded no detectable infectivity when transfected on Sup0 cells but on SupD12 cells at 33ºC gave a yield about 1/10 that of wild-type. This shows that the apparent efficiency of amber suppression was about 10% in SupD12 cells and is consistent with the DNA
replication analysis of Figure 2. The level of amber suppression was lower than the 50 to 70% suppression reported for an amber mutation in a CAT gene in SupD12 cells (Sedivy et al., Cell, 1987, 50:379). However, for a virus such as AAV with a complex growth cycle, the overall level of suppression may reflect cascade effects such as a decreased level of rep protein leading to a further decrease in replication and in the number of single-strands available for encapsidation.
Reversion of the amber mutation in pNTC3.
The experiment of Fig 3 showed that most of the virus particles generated by growth of pNTC3 on the amber suppressor cell lines (SupD3 and SupD12) at 33ºC exhibited an amber mutant phenotype. However, this did not readily determine the level of reversion of the amber mutation.
Reversion of the mutation was examined in two ways. Preparations of pNTC3 were grown in permissive
conditions in SupD12 cells at 33ºC then examined for AAV infectivity under non-permissive conditions in Sup0 cells at 33ºC. Under these conditions only wild-type revertants should score as infectious virus.
Infectivity was measured using either the
immunofluorescence assay (Carter et al., Virology, 1979, 92:449) or a DNA replication assay.
The immunofluorescence assay (Table 2) performed on Sup0 cells at 33ºC showed a few cell nuclei that were positive for AAV capsid fluorescence when stocks of pNTC3 grown on SupD12 at 33ºC were examined. Thus, some wild-type revertants apparently existed in the virus population. In contrast, no infectious virus were detected in lysates of Sup0 cells infected with pNTC3 (Table 2). However the immunofluorescence assay for AAV infectivity relies on the ability to detect the level at which 63% of the maximum number of nuclei are fluorescent for AAV capsid antigen. Thus, the actual titer of the revertants could not be determined readily because the number of fluorescent nuclei was too low and only the extreme end point of the titration was detected. Nevertheless, the titer of the pNTC3 derived virus grown on SupD12 cells was at least five orders of
magnitude lower than that of the virus derived from pNTC244 (Table 2). This showed that the reversion frequency in pNTC3 stocks grown on SupD12 cells at 33ºC was less than 10-5 and probably less than 10-6.
As an alternate measure of reversion, a DNA
replication assay was used (Figure 4). In this assay, Sup0 cells were infected with serial dilutions of virus stocks and viral DNA replication was measured. The level of RF DNA replication thus reflected the level of infecting wild-type genomes and depended upon the presence of a functional rep gene.
A stock of wild-type AAV, originally grown from pNTC244 in SupD12 cells, showed a similar infectivity titration in either SupD12 or Sup0 cells at 33ºC (Fig. 4). A stock of mutant virus grown in parallel from pNTC3 had about 10 fold less infectivity than the wildtype stock in SupD12 cells. This is consistent with the data above (Table 2) that the yield of mutant virus was only about 10% of that of wild-type when grown in SupD12 cells. Prolonged autoradiographic exposure of the gel in Fig. 4 (not shown) also detected replication of pNTC3 virus in SupD12 cells in the 10-5 dilution and an even fainter signal only in the 10º dilution of pNTC3 in the Sup0 cells. Thus, level of reversion is less than 10-5 and probably below 10-6. This is
consistent with the data in Table 2.
Suppression of the amber mutant in SupD12 cells Yields synthesis of rep protein.
Suppression of the amber mutation in pNTC3
presumably resulted in synthesis of rep proteins at the permissive temperature in SupD12 and SupD3 cells. Rep proteins could not be easily detected in adenovirus-
infected SupD12 or SupD3 cells after transfection at 33ºC with pNTC3 although they could be detected after transfection with pNTC244 (data not shown). This reflected much lower expression of rep proteins after transfection with AAV plasmids than after AAV particlemediated infections. Also, the efficiency of
suppression of the mutation in pNTC3 was only about 10% when grown on SupD12 cells.
To demonstrate that amber suppression did allow synthesis of rep protein from the amber mutant genome, the experiment shown in Figure 5 was performed. Virus stocks containing wild-type or amber mutant genomes were generated from pNTC244 or pNTC3 respectively in SupD12 cells and used to infect SupD12 or Sup0 cells at 33ºC. Wild-type AAV expressed similar amounts of the rep proteins in either cell line. The amber mutant expressed about 10 fold less amounts of both major rep proteins, rep78 and rep52 in SupD12 cells but not in Sup0 cells. These results showed that the amber suppressor did allow expression of rep proteins but at a lower overall efficiency than for wild type. Thus, the less efficient DNA replication and infectious virus production by the amber mutant was reflected in a lower level of rep protein synthesis.
Use of amber mutant AAV to generate AAV transducing vectors.
Identification of rep proteins and genetic analysis using mutant AAV plasmids has shown that rep is
required for DNA replication in DNA-mediated
infections. Furthermore, the accumulated evidence indicates that rep is required in normal AAV particlemediated infections. The level of duplex RF
replication and the yield of infectious virus for the amber mutant appears to reflect the level of
suppression of the rep mutation and thus reflects the level of rep protein.
Using procedures analogous to those described herein for the rep gene, we have also constructed an amber mutation in the cap gene of AAV to block
synthesis of the capsid proteins VP1, VP2, VP3 (J.
Smuda, N. Chejanovsky, B.J. Carter, manuscript in preparation). The cap mutation can also be suppressed efficiently as for the rep gene to provide capsid proteins without generating a wild type cap gene.
Thus, both classes of suppressible mutant genes may be used to supply AAV rep and/or cap gene functions under conditions in which infectious wild type AAV is not generated. These mutant rep or cap genes can be supplied as part of an AAV vector by a cotransfecting DNA molecule or as part of the infecting helper
adenovirus or by stable maintenance of these genes in cell lines containing an inducible suppressor. These mutant genes can allow replication and packaging of AAV vectors (not containing a functional rep or cap gene) into AAV particles, under conditions where
recombination does not yield wild type infectious AAV or wild type functional rep or cap genes, to produce high levels of AAV particles containing the vector.
Vectors containing foreign genes or cDNA may be packaged into AAV particles by the method of the invention. Such vectors produced by the inventive techniques may be used to infect suitable cell cultures to produce high levels of proteins such as hormones, growth factors, enzymes or pharmacologically useful
proteins. Furthermore, AAV vectors produced by the inventive means may be used to introduce genes or parts of genes into cells or patients for the purposes of diagnosing, alleviating or correcting genetic diseases or other diseases.
Use of mutant virus to assay mutagenesis in cultured human cells.
The inventive procedure produces pure populations of mutant virus which may be used as the basis of an assay for mutagenesis in cultured human cells and thus for screening potential mutagenic and carcinogenic agents. Such agents may be tested by their effect on the reversion frequency of the mutant virus.
The use of the invention to detect mutagenesis in cultured human cells is demonstrated in the experiment shown in Figure 6. In this experiment human HeLaJW cells were first infected with the AAVam virus stocks then treated with various mutagenic agents. Helper adenovirus was then added to the cells and stocks of progeny AAV were harvested 60 hr later. These AAV stocks were then used to infect fresh HeLaJW cells in the presence of adenovirus (But in the absence of any mutagen) and AAV DNA synthesis was measured. HeLaJW cells do not contain an amber suppressor. In these cells AAVam can only generate progeny AAV if reversion of the amber mutation occurs.
In the experiment of Fig. 6 the negative controls of uninfected cells (track 10) or cells infected only with adenovirus (track 9) yielded no progeny virus. Similarly in the positive controls (tracks 1-4, 11-14) HeLaJW cells infected with AAV wt yielded large amounts of progeny AAV in the presence (tracks 1-4, 11-13) or
absence (track 14) of mutagen treatment.
In Figure 6 control cells infected with AAVam and treated only with dimethylsulfoxide (not known to be a mutagen) yielded not detectable progeny virus. Thus spontaneous reversion (as noted above) was extremely low. When the AAVam infected cells were treated with the mutagen MNNG (tracks 5,6) or DMBA (tracks 7,8) very high levels of progeny AAV were generated and the levels of AAV DNA replication approached those of the wild type virus. Thus both mutagens induced reversion to wild type or pseudo-wild type or both. Hydroxyurea (track 15) also induced reversion of AAVam but at a lower level. Also with BUdR (tracks 16,17) there was a low but detectable production of progeny revertant virus which was more readily seen in longer
autoradiographic exposures (not shown).
The invention of the mutant AAV provides a novel assay for screening mutagenicity of compounds in human (or other mammalian) cells. Various assays for
mutagenesis have been proposed previously for use in mammalian cells but many of these use shuttle vectors to measure the "forward" mutation rate of an active gene from a wild type to a mutant phenotype. However, the spontaneous rate of such mutations is frequently prohibitively high to readily measure the specific effect of mutagens in inducing such forward mutations.
Mutagenicity of any agent may be evaluated by any method which provides for growth of a cell line which has been infected with a virus containing an amber mutation in an essential AAV gene in the presence of a putative genotoxic agent. The mutagenicity of the putative genotoxic agent is evidenced by increased
incidence of wild type or pseudo wild type virus, as measured by viral DNA or proteins.
It was pointed out recently (Greenspan et al., Mol. Cell. Biol., 8:4185-4189) that analysis of the effect of mutagens on reversion to wild type is much more sensitive because the spontaneous rate of reversion is much lower than the forward rate. The invention described here has this advantage and several other potential advantages. First, the mutant virus can be infected into cells of any human or other mammalian tissue eg. liver, lung. Second, wild type (and thus revertant) AAV will grow in any human cells from any tissue provided a helper adenovirus is present (Carter, Handbook of Parvoviruses Vol. 1, CRC Press, 1989 pp 255-282). Thus the invention will be useful for analysing mutagenic effects of compounds whose
mutagenic or genotoxic effect is actually mediated by an intermediate metabolite which is generated by tissue specific enzymes. In contrast, most shuttle vectors previously designed for mutagenesis assays in mammalian cells are restricted in their replication to specific types of cells or even specific host. Third, in a normal AAV growth cycle a single infectious unit generates from one infected cell a burst of up to 104 infectious units which represents up to 106 AAV genomes (Carter et al., Virology 1979, 92:449). Thus one mutagenic event per 106 cells treated with mutagen can yield 104 infectious units. When 25% of this lysate was used to infect a second culture of 106 HeLa cells (as in the experiment of Figure 6) a similar amplification occurs. Thus one mutagenic event can give 1010 AAV genomes in the second culture. This represents an
enormous amplification of the signal from the initial mutagenic event thus increasing the sensitivity of the assay. It also has practical advantages since this large number of genomes is amendable to rapid assay using automated procedures and various types of nucleic acid hybridization assay or various immunological assays for either AAV rep protein or AAV capsid
proteins. Such rep and capsid proteins are clearly defined and specific antibodies have been developed (Mendelson et al., J. Virology 1986, 60:823; Trempe et al., Virology 1987, 161:18; Carter et al., Virology
1979, 92:449).
A fourth novel feature of the present invention is that the AAV genome in the infecting particle is single-stranded DNA. All other shuttle vectors or mammalian viruses suggested for mutagenesis assays have double stranded DNA genomes. Because the infecting AAVam genome is single-stranded (prior to conversion to the first double strand intermediate by host cell enzymes) it offers a unique type of target which may detect additional mutagenic events more readily than with double stranded genomes.
Finally, several extensions of the present
invention are now obvious. As noted above other types of human or mammalian cells can be used for mutagen testing. Secondly, other types of mutations can be introduced into the AAV genome, such as nonsense mutations at other serine or non-serine codons or in non-essential regions of the rep or capsid protein. This would allow design of the system to detect certain classes of reversion such as transitions or
transversions. Also, introduction of additional
nucleotides or deletion of one or two nucleotides would allow testing for compounds that cause frameshift mutations. Also, location of mutations within non-essential regions of rep or capsid genes would permit detection of reversion due to deletions. Generation of cell lines containing the AAVam genome integrated into the cellular chromosome would provide a highly
sensitive assay for reversion because treatment of such cells with mutagens leading to reversion of the am mutation would render the integrated AAV genome
rescuable and amplifiable upon superinfection with a helper virus (eg. adenovirus).
E. coli. containing the plasmid pNTC3 has been deposited in the American Type Culture Collection in Rockville, Maryland under the provisions of the
Budapest Treaty and will be maintained for at least 30 years following issuance of the patent. The accession number is 68000 and was received on June 1, 1989.
Table I
Growth of AAV2 on monkey cell linesa
AVV2 titer atb:
Cell 33ºC 39.5ºC line
BSC Sup0 4.8 × 108 7.2 × 109
BSC SupD3 4.8 × 108 3.2 × 109
BSC SupD12 5.6 × 108 5.6 × 109
a. Cells were plated in 60 mm dishes at approximately 106 cells per dish and grown at 39.5ºC or 33.0ºC then infected with AAV2 (1 i.u./cell) and Ad5 (5 i.u./cell). For cultures placed at 39.5ºC, cells were infected after 24 hr and lysates for AAV assay were prepared at 48 hr after infection. For
cultures placed at 33 C, cells were infected with AAV2 and Ad5 after 48 hr and virus assay lysates were prepared at 72 hr after infection.
b. Lysates were frozen and thawed six times, heated at 60ºC for 20 min and clarified by low speed
centrifugation. The AAV virus titer was determined using the fluorescent focus assay (Carter et al., Virology, 1979, 92:449) on Hela cells.
Table 2
Infectious titer of wild type and mutant AAV stocks
AAV2 infectivity assayed inb
Virus Grown
stocka on:
SupD12 Sup0
AAV2 (pNTC244) SupD12 4.0 × 108 1.5 × 108
AAV2 (pNTC244) Sup0 3.2 × 10 8 1.4 × 108
AAV2 (pNTC3) SupD12 4.0 × 107 <1.0 × 103
AAV2 (pNTC3) Sup0 0 0a Virus stocks were prepared by transfecting 1 μg of the indicated plasmid onto SupD12 or Sup0 cell at 33ºC. Lysates were prepared at 90 hr after
transfection
b Infectivity of the viral stocks was assayed at 33 C in SupD12 or Sup0 cells using the indirect
immunofluorescence procedure (Carter et al.,
Virology, 1979, 92:449). Titers are expressed as AAV2 infectious units per ml.
Claims
1. A method of evaluating mutagenicity of a putative genotoxic agent comprising the steps of:
(1) infecting a cell culture with a virus containing an amber mutation within the genome;
(2) exposing the infected cell culture produced in step (1) to a putative genotoxic agent; and
(3) evaluating the cell culture produced in step (2) to determine extent of reversion of virus in the culture to wild type or pseudo wild type by
identification and quantitation of viral DNA or protein produced by revertent replicating virus.
2. A procedure of claim 1 used to screen
genotoxic agents or potential genotoxic agents for an effect on reversion frequency of the mutant virus to determine possibility of mutagenic, carcinogenic or genotoxic potential.
3. A comparison of matter comprising a culture of a cell line which has been infected with a virus containing an amber mutation in an essential AAV gene and a putative mutagenic agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54930490A | 1990-07-09 | 1990-07-09 | |
US549,304 | 1990-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992001070A1 true WO1992001070A1 (en) | 1992-01-23 |
Family
ID=24192449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/004765 WO1992001070A1 (en) | 1990-07-09 | 1991-07-09 | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU8200191A (en) |
WO (1) | WO1992001070A1 (en) |
Cited By (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4339352A1 (en) * | 1993-11-18 | 1995-05-24 | Univ Ludwigs Albert | Method for labeling cells, cells labeled with this method, use of the wild-type adeno-associated virus for labeling cells and test kits for detecting the wild-type adeno-associated virus in cells |
WO1996012010A1 (en) * | 1994-10-13 | 1996-04-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Preparation of rep-negative aav mutants and cells which can be used therefor |
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
WO2000011154A1 (en) * | 1998-08-20 | 2000-03-02 | Cell Genesys, Inc. | USE OF SUPPRESSOR tRNA'S TO REGULATE CYTOTOXICITY DURING THE PRODUCTION OF RECOMBINANT GENE PRODUCTS |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US6410236B1 (en) | 1999-09-01 | 2002-06-25 | The Regents Of The University Of Michigan | Correcting diastolic dysfunction in heart failure |
WO2003053220A2 (en) | 2001-12-17 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US6710036B2 (en) | 1997-07-25 | 2004-03-23 | Avigen, Inc. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
WO2004062599A2 (en) | 2003-01-06 | 2004-07-29 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2004106523A1 (en) * | 2003-05-28 | 2004-12-09 | The University Of Hong Kong | Compositions and methods for preventing and treating liver cirrhosis |
WO2005007808A2 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
WO2006020684A2 (en) | 2004-08-10 | 2006-02-23 | Institute For Multiple Myeloma And Bone Cancer Research | Methods of regulating differentiation and treating of multiple myeloma |
EP1650221A2 (en) | 2000-02-23 | 2006-04-26 | GlaxoSmithKline Biologicals SA | Novel compounds |
WO2006130581A2 (en) | 2005-05-31 | 2006-12-07 | Avigen, Inc. | Methods for delivering genes |
WO2007126959A2 (en) | 2006-03-29 | 2007-11-08 | Dana-Farber Cancer Institute | Methods and compositions for inducing an immune response to hiv and models for testing |
US7351577B2 (en) | 1998-10-20 | 2008-04-01 | Genzyme Corporation | Adeno-associated vector compositions for expression of Factor VIII |
US7378273B2 (en) | 2000-07-03 | 2008-05-27 | Gala Design, Inc. | Expression vectors |
US7384738B2 (en) | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
EP1961819A2 (en) | 2000-06-28 | 2008-08-27 | Corixa Corporation | Composition and methods for the therapy and diagnosis of lung cancer |
EP1988097A1 (en) | 2001-05-09 | 2008-11-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP2105502A1 (en) | 2000-12-12 | 2009-09-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7678760B2 (en) | 1999-06-28 | 2010-03-16 | The Board Of Trustees Of The University Of Illinois | Inhibitors of Memapsin 2 and use thereof |
US7691579B2 (en) | 2005-04-15 | 2010-04-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
EP2172476A2 (en) | 2001-10-30 | 2010-04-07 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
WO2010057260A1 (en) | 2008-11-20 | 2010-05-27 | Angioblast Systems, Inc. | Method for treating or preventing a pancreatic dysfunction |
EP2198882A2 (en) | 2001-01-12 | 2010-06-23 | Novartis Vaccines and Diagnostics, Inc. | Nucleic acid mucosal immunization |
EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
WO2010088560A1 (en) | 2009-01-29 | 2010-08-05 | University Of California, San Francisco | Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders |
WO2010129021A1 (en) | 2009-05-02 | 2010-11-11 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
EP2258841A1 (en) | 2003-06-23 | 2010-12-08 | The Regents of the University of Colorado | Methods for treating pain |
US7858590B2 (en) | 2005-08-11 | 2010-12-28 | Cedars-Sinai Medical Center | Treatment of parkinson's disease and related disorders |
EP2277996A2 (en) | 2003-05-21 | 2011-01-26 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
EP2281832A2 (en) | 2000-07-05 | 2011-02-09 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2292772A1 (en) | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide |
EP2298340A1 (en) | 2004-09-22 | 2011-03-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition for use in vaccination against staphylococcei |
EP2298360A2 (en) | 2002-11-21 | 2011-03-23 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
EP2301552A1 (en) | 2001-11-21 | 2011-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
EP2338524A1 (en) | 2004-08-12 | 2011-06-29 | Cedars-Sinai Medical Center | Combined gene therapy for the treatment of macroscopic gliomas |
EP2360175A2 (en) | 2005-11-22 | 2011-08-24 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
WO2011106705A2 (en) | 2010-02-26 | 2011-09-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dna-protein vaccination protocols |
WO2012000064A1 (en) | 2010-07-02 | 2012-01-05 | Angioblast Systems, Inc. | Method of treating graft versus host disease |
EP2412242A2 (en) | 2001-07-05 | 2012-02-01 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
EP2441846A2 (en) | 2006-01-09 | 2012-04-18 | The Regents Of the University of California | Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy |
WO2012049314A1 (en) | 2010-10-15 | 2012-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24 -hydrolase in therapy of huntington' s disease |
US8222188B2 (en) | 2002-03-28 | 2012-07-17 | Catalent Pharma Solutions, Llc | Antibody libraries |
WO2012162758A1 (en) | 2011-06-03 | 2012-12-06 | Mesoblast, Inc | Method of treating the effects of stroke |
WO2012177595A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
WO2013003899A1 (en) | 2011-07-04 | 2013-01-10 | Mesoblast, Inc | Methods of treating or preventing rheumatic disease |
WO2013033777A1 (en) | 2011-09-09 | 2013-03-14 | Mesoblast, Inc | Methods for increasing osteoblastic function |
EP2572661A1 (en) | 2004-10-05 | 2013-03-27 | Genzyme Corporation | Stepped cannula |
US8425922B2 (en) | 2009-01-05 | 2013-04-23 | EpitoGenesis, Inc. | Adjuvant compositions and methods of use |
US8460932B2 (en) | 1999-10-21 | 2013-06-11 | Cedars-Sinai Medical Center | Method of treating a disorder by suicide gene therapy |
US8685720B2 (en) | 2006-11-03 | 2014-04-01 | The Trustees Of Princeton University | Engineered cellular pathways for programmed autoregulation of differentiation |
WO2014089623A1 (en) | 2012-12-12 | 2014-06-19 | Mesoblast, Inc. | Treatment of diseases of endothelial dysfunction and inflammation |
WO2014110053A1 (en) | 2013-01-08 | 2014-07-17 | Genzyme Corporation | Use of inos inhibitors to increase viral yield in culture |
WO2014118346A1 (en) | 2013-02-01 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure |
WO2014144844A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY |
WO2014144521A1 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Mitochondrial-derived peptide mots3 regulates metabolism and cell survival |
WO2014172560A1 (en) | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
US8883493B2 (en) | 2007-01-30 | 2014-11-11 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
US8901079B2 (en) | 2004-08-11 | 2014-12-02 | Cedars-Sinai Medical Center | Treatment of parkinson's disease via administration of GLI-1 protein |
WO2015031686A1 (en) | 2013-08-30 | 2015-03-05 | Amgen Inc. | High titer recombinant aav vector production in adherent and suspension cells |
WO2015067668A1 (en) | 2013-11-05 | 2015-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New alzheimer's disease animal model |
WO2015120309A1 (en) | 2014-02-06 | 2015-08-13 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
WO2015124546A1 (en) | 2014-02-19 | 2015-08-27 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic | Aav vectors for the treatment of ischemic and non-ischemic heart disease |
WO2015143177A1 (en) | 2014-03-21 | 2015-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
EP2940027A1 (en) | 2004-07-08 | 2015-11-04 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
WO2016150964A1 (en) | 2015-03-23 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
WO2016154344A1 (en) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
WO2016177805A1 (en) | 2015-05-05 | 2016-11-10 | Mesoblast International Sàrl | Potency assay |
WO2016183420A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for inducing an immune response using conserved element constructs |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
WO2016198627A1 (en) | 2015-06-12 | 2016-12-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
WO2017004022A2 (en) | 2015-06-29 | 2017-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
WO2017005806A1 (en) | 2015-07-07 | 2017-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject |
US9644215B2 (en) | 2013-04-12 | 2017-05-09 | The General Hospital Corporation | AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors |
WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
WO2017143100A1 (en) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
WO2017173283A1 (en) | 2016-03-31 | 2017-10-05 | Spark Therapeutics, Inc. | Column-based fully scalable raav manufacturing process |
WO2018138360A1 (en) | 2017-01-28 | 2018-08-02 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | Oxygen carrying blood substitutes and their use as delivery vehicles |
WO2018138371A1 (en) | 2017-01-30 | 2018-08-02 | Brainvectis | Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias |
EP3378483A1 (en) | 2008-06-25 | 2018-09-26 | Mesoblast, Inc. | Repair and/or reconstitution of invertebral discs |
WO2018172527A1 (en) | 2017-03-24 | 2018-09-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of neurodegenerative disease |
WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
WO2018202853A1 (en) | 2017-05-04 | 2018-11-08 | Mesoblast International Sàrl | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
US10377801B2 (en) | 2015-11-04 | 2019-08-13 | Northwestern University | Amelioration of chronic kidney disease |
US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
WO2019175380A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019175381A1 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019191701A1 (en) | 2018-03-30 | 2019-10-03 | The Board Of Trustees Of Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
WO2019219649A1 (en) | 2018-05-14 | 2019-11-21 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
WO2020016318A1 (en) | 2018-07-17 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
WO2020074690A1 (en) | 2018-10-12 | 2020-04-16 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
WO2020089154A1 (en) | 2018-10-29 | 2020-05-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis |
WO2020094693A1 (en) | 2018-11-07 | 2020-05-14 | Vivet Therapeutics | Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2) |
US10669320B2 (en) | 2015-11-18 | 2020-06-02 | The Regents Of The University Of Michigan | Mps1 and KNL1 phosphorylation system |
US10703797B2 (en) | 2018-07-12 | 2020-07-07 | Rocket Pharmaceuticals, Ltd. | Gene therapy vectors for treatment of Danon disease |
WO2020141483A1 (en) | 2019-01-03 | 2020-07-09 | Mesoblast International Sàrl | Method for improving visual acuity |
WO2020141473A1 (en) | 2019-01-02 | 2020-07-09 | Mesoblast International Sárl | Method for treating lower back pain |
WO2020193441A1 (en) | 2019-03-22 | 2020-10-01 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
WO2020234363A2 (en) | 2019-05-21 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome |
WO2020234450A1 (en) | 2019-05-23 | 2020-11-26 | Mesoblast International Sarl | Functional recovery from cerebral infarction |
EP3744351A1 (en) | 2014-12-17 | 2020-12-02 | Fundacion para la Investigacion Medica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions |
WO2021001377A1 (en) | 2019-07-02 | 2021-01-07 | Fundacion Para La Investigacion Medica Aplicada | cPLA2e INDUCING AGENTS AND USES THEREOF |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
EP3799889A1 (en) | 2014-12-17 | 2021-04-07 | Fundacion para la Investigacion Medica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease and other conditions |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
US11065347B2 (en) | 2016-01-19 | 2021-07-20 | The Regents Of The University Of California | Methods for the treatment of Danon disease and other disorders of autophagy |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
WO2021239838A2 (en) | 2020-05-26 | 2021-12-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
WO2021250079A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies |
WO2021250076A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Treatment of genetic dilated cardiomyopathies |
WO2021250081A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Nrf2 activator for use in treating dilated cardiomyopathies |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
WO2022029322A2 (en) | 2020-08-06 | 2022-02-10 | Fundacion Para La Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
WO2022033983A1 (en) | 2020-08-10 | 2022-02-17 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
WO2022069598A1 (en) | 2020-09-29 | 2022-04-07 | Genethon | Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof |
WO2022074105A1 (en) | 2020-10-09 | 2022-04-14 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
WO2022101463A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death |
WO2022136616A1 (en) | 2020-12-23 | 2022-06-30 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
WO2023012165A1 (en) | 2021-08-02 | 2023-02-09 | Universite De Montpellier | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 |
WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
WO2023073071A1 (en) | 2021-10-28 | 2023-05-04 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023150563A1 (en) | 2022-02-01 | 2023-08-10 | Cornell University | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia |
WO2023183588A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of assessing engineered retron activity, and uses thereof |
WO2023183627A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
WO2023183589A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Rt-dna fidelity and retron genome editing |
EP4045636A4 (en) * | 2019-10-15 | 2023-11-29 | University of Massachusetts | Aav production strategy using a cell line expressing an inducible rep gene |
WO2024011237A1 (en) | 2022-07-08 | 2024-01-11 | Cornell University | Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
US11883506B2 (en) | 2020-08-07 | 2024-01-30 | Spacecraft Seven, Llc | Plakophilin-2 (PKP2) gene therapy using AAV vector |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
WO2024079317A1 (en) | 2022-10-14 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies |
-
1991
- 1991-07-09 WO PCT/US1991/004765 patent/WO1992001070A1/en unknown
- 1991-07-09 AU AU82001/91A patent/AU8200191A/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
CELL, Volume 50, issued 31 July 1987, JOHN M. SEDIVY et al., "An Inducible Mammalian Amber Suppressor: Propagation of a Poliovirus Mutant", pages 379-389. * |
GENE, Volume 23, issued 1983, CATHERINE A. LAUGHLIN et al., "Cloning of infectious adeno-associated virus genomes in bacterial plasmids", pages 65-73. * |
PROCEDDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 79, issued March 1982, R.J. SAMULSKI et al., "Cloning of the adeno-associated virus into pBR322: Rescue of intact from the recombinant plasmid in human cells", pages 2077-2081. * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 81, issued October 1984, PAUL L. HERMONAT et al., "Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells", pages 6466-6470. * |
Cited By (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4339352A1 (en) * | 1993-11-18 | 1995-05-24 | Univ Ludwigs Albert | Method for labeling cells, cells labeled with this method, use of the wild-type adeno-associated virus for labeling cells and test kits for detecting the wild-type adeno-associated virus in cells |
WO1995014232A1 (en) * | 1993-11-18 | 1995-05-26 | KLINIKUM DER ALBERT-LUDWIGS-UNIVERSITäT FREIBURG | Method for marking cells; cells marked using this method; use of wild-type adeno-associated virus for marking cells, and test kits for detecting wild-type adeno-associated virus in cells |
WO1996012010A1 (en) * | 1994-10-13 | 1996-04-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Preparation of rep-negative aav mutants and cells which can be used therefor |
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
US6710036B2 (en) | 1997-07-25 | 2004-03-23 | Avigen, Inc. | Induction of immune response to antigens expressed by recombinant adeno-associated virus |
WO2000011154A1 (en) * | 1998-08-20 | 2000-03-02 | Cell Genesys, Inc. | USE OF SUPPRESSOR tRNA'S TO REGULATE CYTOTOXICITY DURING THE PRODUCTION OF RECOMBINANT GENE PRODUCTS |
AU775679B2 (en) * | 1998-08-20 | 2004-08-12 | Cell Genesys, Inc. | Use of suppressor tRNA's to regulate cytotoxicity during the production of recombinant gene products |
US6586208B2 (en) | 1998-08-20 | 2003-07-01 | Cell Genesys, Inc. | Use of suppressor tRNA's to regulate cytotoxicity during the production of recombinant gene products |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US7351577B2 (en) | 1998-10-20 | 2008-04-01 | Genzyme Corporation | Adeno-associated vector compositions for expression of Factor VIII |
EP2206785A1 (en) | 1998-12-31 | 2010-07-14 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
US7829669B2 (en) | 1999-06-28 | 2010-11-09 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
US7678760B2 (en) | 1999-06-28 | 2010-03-16 | The Board Of Trustees Of The University Of Illinois | Inhibitors of Memapsin 2 and use thereof |
US6410236B1 (en) | 1999-09-01 | 2002-06-25 | The Regents Of The University Of Michigan | Correcting diastolic dysfunction in heart failure |
US8460932B2 (en) | 1999-10-21 | 2013-06-11 | Cedars-Sinai Medical Center | Method of treating a disorder by suicide gene therapy |
EP1650221A2 (en) | 2000-02-23 | 2006-04-26 | GlaxoSmithKline Biologicals SA | Novel compounds |
EP1961819A2 (en) | 2000-06-28 | 2008-08-27 | Corixa Corporation | Composition and methods for the therapy and diagnosis of lung cancer |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
US7378273B2 (en) | 2000-07-03 | 2008-05-27 | Gala Design, Inc. | Expression vectors |
EP2311958A2 (en) | 2000-07-05 | 2011-04-20 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2281832A2 (en) | 2000-07-05 | 2011-02-09 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2105502A1 (en) | 2000-12-12 | 2009-09-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
EP2198882A2 (en) | 2001-01-12 | 2010-06-23 | Novartis Vaccines and Diagnostics, Inc. | Nucleic acid mucosal immunization |
EP1988097A1 (en) | 2001-05-09 | 2008-11-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP2292772A1 (en) | 2001-07-05 | 2011-03-09 | Novartis Vaccines and Diagnostics, Inc. | HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide |
EP2412242A2 (en) | 2001-07-05 | 2012-02-01 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
EP2172476A2 (en) | 2001-10-30 | 2010-04-07 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
EP2322185A2 (en) | 2001-11-21 | 2011-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
EP2301552A1 (en) | 2001-11-21 | 2011-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
EP2301553A1 (en) | 2001-11-21 | 2011-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
WO2003053220A2 (en) | 2001-12-17 | 2003-07-03 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
EP2224012A1 (en) | 2001-12-17 | 2010-09-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US8222188B2 (en) | 2002-03-28 | 2012-07-17 | Catalent Pharma Solutions, Llc | Antibody libraries |
US7384738B2 (en) | 2002-03-28 | 2008-06-10 | Bremel Robert D | Retrovirus-based genomic screening |
EP2353614A1 (en) | 2002-11-21 | 2011-08-10 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
EP2322186A2 (en) | 2002-11-21 | 2011-05-18 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
EP2329827A2 (en) | 2002-11-21 | 2011-06-08 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
EP2298360A2 (en) | 2002-11-21 | 2011-03-23 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
WO2004062599A2 (en) | 2003-01-06 | 2004-07-29 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
EP2940028A1 (en) | 2003-01-06 | 2015-11-04 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2005007808A2 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
EP2277996A2 (en) | 2003-05-21 | 2011-01-26 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
EP2781596A1 (en) | 2003-05-21 | 2014-09-24 | Genzyme Corporation | Methods for producing prepartions of recombinant AAVvirions substantially free of empty capsids |
EP2281877A2 (en) | 2003-05-21 | 2011-02-09 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
WO2004106523A1 (en) * | 2003-05-28 | 2004-12-09 | The University Of Hong Kong | Compositions and methods for preventing and treating liver cirrhosis |
EP2258841A1 (en) | 2003-06-23 | 2010-12-08 | The Regents of the University of Colorado | Methods for treating pain |
EP2940027A1 (en) | 2004-07-08 | 2015-11-04 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
WO2006020684A2 (en) | 2004-08-10 | 2006-02-23 | Institute For Multiple Myeloma And Bone Cancer Research | Methods of regulating differentiation and treating of multiple myeloma |
US8901079B2 (en) | 2004-08-11 | 2014-12-02 | Cedars-Sinai Medical Center | Treatment of parkinson's disease via administration of GLI-1 protein |
EP2338524A1 (en) | 2004-08-12 | 2011-06-29 | Cedars-Sinai Medical Center | Combined gene therapy for the treatment of macroscopic gliomas |
US8420611B2 (en) | 2004-08-12 | 2013-04-16 | Cedars-Sinai Medical Center | Combined gene therapy for the treatment of macroscopic gliomas |
EP2305296A1 (en) | 2004-09-22 | 2011-04-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
EP2305295A1 (en) | 2004-09-22 | 2011-04-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
EP2305294A1 (en) | 2004-09-22 | 2011-04-06 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
EP2893938A1 (en) | 2004-09-22 | 2015-07-15 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against Staphylococcei |
EP2298340A1 (en) | 2004-09-22 | 2011-03-23 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition for use in vaccination against staphylococcei |
EP2572661A1 (en) | 2004-10-05 | 2013-03-27 | Genzyme Corporation | Stepped cannula |
US7691579B2 (en) | 2005-04-15 | 2010-04-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
WO2006130581A2 (en) | 2005-05-31 | 2006-12-07 | Avigen, Inc. | Methods for delivering genes |
EP2816118A1 (en) | 2005-05-31 | 2014-12-24 | The Regents of the University of Colorado, A Body Corporate | Methods for delivering genes |
US7858590B2 (en) | 2005-08-11 | 2010-12-28 | Cedars-Sinai Medical Center | Treatment of parkinson's disease and related disorders |
EP2360175A2 (en) | 2005-11-22 | 2011-08-24 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
EP2441846A2 (en) | 2006-01-09 | 2012-04-18 | The Regents Of the University of California | Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy |
WO2007126959A2 (en) | 2006-03-29 | 2007-11-08 | Dana-Farber Cancer Institute | Methods and compositions for inducing an immune response to hiv and models for testing |
US8685720B2 (en) | 2006-11-03 | 2014-04-01 | The Trustees Of Princeton University | Engineered cellular pathways for programmed autoregulation of differentiation |
US9458471B2 (en) | 2006-11-03 | 2016-10-04 | The Trustees Of Princeton University | Engineered cellular pathways for programmed autoregulation of differentiation |
US8883493B2 (en) | 2007-01-30 | 2014-11-11 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
EP3378483A1 (en) | 2008-06-25 | 2018-09-26 | Mesoblast, Inc. | Repair and/or reconstitution of invertebral discs |
WO2010057260A1 (en) | 2008-11-20 | 2010-05-27 | Angioblast Systems, Inc. | Method for treating or preventing a pancreatic dysfunction |
EP3002329A1 (en) | 2008-11-20 | 2016-04-06 | Mesoblast, Inc. | Method for treating or preventing a pancreatic dysfunction |
US9180184B2 (en) | 2009-01-05 | 2015-11-10 | EpitoGenesis, Inc. | Adjuvant compositions and methods of use |
US8425922B2 (en) | 2009-01-05 | 2013-04-23 | EpitoGenesis, Inc. | Adjuvant compositions and methods of use |
WO2010088560A1 (en) | 2009-01-29 | 2010-08-05 | University Of California, San Francisco | Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders |
EP3421603A1 (en) | 2009-05-02 | 2019-01-02 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
EP4342992A2 (en) | 2009-05-02 | 2024-03-27 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
EP3988660A1 (en) | 2009-05-02 | 2022-04-27 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
WO2010129021A1 (en) | 2009-05-02 | 2010-11-11 | Genzyme Corporation | Gene therapy for neurodegenerative disorders |
WO2011106705A2 (en) | 2010-02-26 | 2011-09-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dna-protein vaccination protocols |
EP3366298A1 (en) | 2010-07-02 | 2018-08-29 | Mesoblast, Inc. | Method of treating graft versus host disease |
WO2012000064A1 (en) | 2010-07-02 | 2012-01-05 | Angioblast Systems, Inc. | Method of treating graft versus host disease |
WO2012049314A1 (en) | 2010-10-15 | 2012-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24 -hydrolase in therapy of huntington' s disease |
EP3513797A1 (en) | 2011-06-03 | 2019-07-24 | Mesoblast, Inc. | Method of treating the effects of stroke |
WO2012162758A1 (en) | 2011-06-03 | 2012-12-06 | Mesoblast, Inc | Method of treating the effects of stroke |
WO2012177595A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
EP3653218A1 (en) | 2011-07-04 | 2020-05-20 | Mesoblast, Inc. | Methods of treating or preventing rheumatic disease |
WO2013003899A1 (en) | 2011-07-04 | 2013-01-10 | Mesoblast, Inc | Methods of treating or preventing rheumatic disease |
WO2013033777A1 (en) | 2011-09-09 | 2013-03-14 | Mesoblast, Inc | Methods for increasing osteoblastic function |
EP3351256A1 (en) | 2011-09-09 | 2018-07-25 | Mesoblast, Inc. | Method for increasing osteoblastic function |
EP3556850A1 (en) | 2012-12-12 | 2019-10-23 | Mesoblast, Inc. | Treatment of diseases of endothelial dysfunction and inflammation |
WO2014089623A1 (en) | 2012-12-12 | 2014-06-19 | Mesoblast, Inc. | Treatment of diseases of endothelial dysfunction and inflammation |
EP3266866A1 (en) | 2013-01-08 | 2018-01-10 | Genzyme Corporation | Use of inos inhibitors to increase viral yield in culture |
WO2014110053A1 (en) | 2013-01-08 | 2014-07-17 | Genzyme Corporation | Use of inos inhibitors to increase viral yield in culture |
EP3521420A1 (en) | 2013-01-08 | 2019-08-07 | Genzyme Corporation | Use of inos inhibitors to increase viral yield in culture |
WO2014118346A1 (en) | 2013-02-01 | 2014-08-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure |
EP4324845A2 (en) | 2013-02-01 | 2024-02-21 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure |
WO2014144844A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY |
WO2014144521A1 (en) | 2013-03-15 | 2014-09-18 | The Regents Of The University Of California | Mitochondrial-derived peptide mots3 regulates metabolism and cell survival |
US9644215B2 (en) | 2013-04-12 | 2017-05-09 | The General Hospital Corporation | AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors |
US10640771B2 (en) | 2013-04-17 | 2020-05-05 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
EP3741385A1 (en) | 2013-04-17 | 2020-11-25 | Genzyme Corporation | Compositions for use in a method of treating and preventing macular degeneration |
WO2014172560A1 (en) | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
US11834683B2 (en) | 2013-08-30 | 2023-12-05 | Amgen Inc. | High titer recombinant AAV vector production in adherent and suspension cells |
US11078464B2 (en) | 2013-08-30 | 2021-08-03 | Amgen Inc. | High titer recombinant AAV vector production in adherent and suspension cells |
WO2015031686A1 (en) | 2013-08-30 | 2015-03-05 | Amgen Inc. | High titer recombinant aav vector production in adherent and suspension cells |
WO2015067668A1 (en) | 2013-11-05 | 2015-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New alzheimer's disease animal model |
US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
WO2015120309A1 (en) | 2014-02-06 | 2015-08-13 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
WO2015124546A1 (en) | 2014-02-19 | 2015-08-27 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii- Cnic | Aav vectors for the treatment of ischemic and non-ischemic heart disease |
US10612041B2 (en) | 2014-03-21 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
WO2015143177A1 (en) | 2014-03-21 | 2015-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
EP3799889A1 (en) | 2014-12-17 | 2021-04-07 | Fundacion para la Investigacion Medica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson disease and other conditions |
EP3744351A1 (en) | 2014-12-17 | 2020-12-02 | Fundacion para la Investigacion Medica Aplicada | Nucleic acid constructs and gene therapy vectors for use in the treatment of wilson's disease and other conditions |
EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
EP3054006A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
US11203740B2 (en) | 2015-02-09 | 2021-12-21 | Institut National De La Sante De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
WO2016128408A1 (en) | 2015-02-09 | 2016-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an affinity purification step |
WO2016128407A1 (en) | 2015-02-09 | 2016-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography |
US11021689B2 (en) | 2015-02-09 | 2021-06-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an affinity purification step |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
WO2016150964A1 (en) | 2015-03-23 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment and the prevention of neurological phenotype associated with friedreich ataxia |
WO2016154344A1 (en) | 2015-03-24 | 2016-09-29 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
WO2016177805A1 (en) | 2015-05-05 | 2016-11-10 | Mesoblast International Sàrl | Potency assay |
EP4015624A1 (en) | 2015-05-05 | 2022-06-22 | Mesoblast International Sàrl | Potency assay |
EP4276106A2 (en) | 2015-05-13 | 2023-11-15 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for inducing an immune response using conserved element constructs |
WO2016183420A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for inducing an immune response using conserved element constructs |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
WO2016198627A1 (en) | 2015-06-12 | 2016-12-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
WO2017004022A2 (en) | 2015-06-29 | 2017-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
WO2017005806A1 (en) | 2015-07-07 | 2017-01-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject |
US10377801B2 (en) | 2015-11-04 | 2019-08-13 | Northwestern University | Amelioration of chronic kidney disease |
US10669320B2 (en) | 2015-11-18 | 2020-06-02 | The Regents Of The University Of Michigan | Mps1 and KNL1 phosphorylation system |
US10406244B2 (en) | 2015-12-02 | 2019-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | AAV vectors with expanded packaging capacity |
WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
US10385320B2 (en) | 2015-12-02 | 2019-08-20 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
US11065347B2 (en) | 2016-01-19 | 2021-07-20 | The Regents Of The University Of California | Methods for the treatment of Danon disease and other disorders of autophagy |
EP4119168A1 (en) | 2016-01-19 | 2023-01-18 | The Regents of the University of California | Methods for the treatment of danon disease and other disorders of autophagy |
US10179176B2 (en) | 2016-02-16 | 2019-01-15 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
WO2017143100A1 (en) | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies |
WO2017173283A1 (en) | 2016-03-31 | 2017-10-05 | Spark Therapeutics, Inc. | Column-based fully scalable raav manufacturing process |
US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
WO2018138360A1 (en) | 2017-01-28 | 2018-08-02 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | Oxygen carrying blood substitutes and their use as delivery vehicles |
WO2018138371A1 (en) | 2017-01-30 | 2018-08-02 | Brainvectis | Expression vector for cholesterol 24-hydrolase in therapy of polyglutamine repeat spinocerebellar ataxias |
WO2018172527A1 (en) | 2017-03-24 | 2018-09-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of neurodegenerative disease |
WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
WO2018202853A1 (en) | 2017-05-04 | 2018-11-08 | Mesoblast International Sàrl | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
EP4137562A1 (en) | 2017-05-04 | 2023-02-22 | Mesoblast International Sàrl | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression |
WO2019175380A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019175381A1 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
WO2019191701A1 (en) | 2018-03-30 | 2019-10-03 | The Board Of Trustees Of Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
US11608510B2 (en) | 2018-03-30 | 2023-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism |
WO2019219649A1 (en) | 2018-05-14 | 2019-11-21 | Vivet Therapeutics | Gene therapy vectors comprising s/mar sequences |
US10703797B2 (en) | 2018-07-12 | 2020-07-07 | Rocket Pharmaceuticals, Ltd. | Gene therapy vectors for treatment of Danon disease |
WO2020016318A1 (en) | 2018-07-17 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
EP4154904A1 (en) | 2018-07-17 | 2023-03-29 | Institut National De La Sante Et De La Recherche Medicale - Inserm | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
WO2020074690A1 (en) | 2018-10-12 | 2020-04-16 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
EP4223320A2 (en) | 2018-10-12 | 2023-08-09 | Vivet Therapeutics | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) |
EP4205757A1 (en) | 2018-10-29 | 2023-07-05 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Expression vector for cholesterol 24-hydrolase for the prevention of amyotrophic lateral sclerosis |
WO2020089154A1 (en) | 2018-10-29 | 2020-05-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis |
WO2020094693A1 (en) | 2018-11-07 | 2020-05-14 | Vivet Therapeutics | Codon-optimized abcb11 transgene for the treatment of progressive familial intrahepatic cholestasis type 2 (pfic2) |
WO2020141473A1 (en) | 2019-01-02 | 2020-07-09 | Mesoblast International Sárl | Method for treating lower back pain |
WO2020141483A1 (en) | 2019-01-03 | 2020-07-09 | Mesoblast International Sàrl | Method for improving visual acuity |
WO2020193441A1 (en) | 2019-03-22 | 2020-10-01 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
WO2020234363A2 (en) | 2019-05-21 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome |
WO2020234450A1 (en) | 2019-05-23 | 2020-11-26 | Mesoblast International Sarl | Functional recovery from cerebral infarction |
WO2021001377A1 (en) | 2019-07-02 | 2021-01-07 | Fundacion Para La Investigacion Medica Aplicada | cPLA2e INDUCING AGENTS AND USES THEREOF |
WO2022008725A1 (en) | 2019-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds for use in the treatment of epilepsy |
WO2021005223A1 (en) | 2019-07-10 | 2021-01-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of epilepsy |
EP4045636A4 (en) * | 2019-10-15 | 2023-11-29 | University of Massachusetts | Aav production strategy using a cell line expressing an inducible rep gene |
WO2021099394A1 (en) | 2019-11-19 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antisense oligonucleotides and their use for the treatment of cancer |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
WO2021239838A2 (en) | 2020-05-26 | 2021-12-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
WO2021250079A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies |
WO2021250081A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Nrf2 activator for use in treating dilated cardiomyopathies |
WO2021250076A1 (en) | 2020-06-09 | 2021-12-16 | Genethon | Treatment of genetic dilated cardiomyopathies |
WO2022011262A1 (en) | 2020-07-10 | 2022-01-13 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating epilepsy |
WO2022029322A2 (en) | 2020-08-06 | 2022-02-10 | Fundacion Para La Investigacion Medica Aplicada | Viral particles for use in treating tauopathies such as alzheimer's diseases by gene therapy |
US11883506B2 (en) | 2020-08-07 | 2024-01-30 | Spacecraft Seven, Llc | Plakophilin-2 (PKP2) gene therapy using AAV vector |
WO2022033983A1 (en) | 2020-08-10 | 2022-02-17 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
WO2022069598A1 (en) | 2020-09-29 | 2022-04-07 | Genethon | Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof |
WO2022074105A1 (en) | 2020-10-09 | 2022-04-14 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
WO2022101463A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death |
WO2022136616A1 (en) | 2020-12-23 | 2022-06-30 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
WO2023012165A1 (en) | 2021-08-02 | 2023-02-09 | Universite De Montpellier | Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22 |
WO2023070072A1 (en) | 2021-10-21 | 2023-04-27 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Retroelement-generated transcription factor decoys |
WO2023073071A1 (en) | 2021-10-28 | 2023-05-04 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023150563A1 (en) | 2022-02-01 | 2023-08-10 | Cornell University | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia |
WO2023183589A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Rt-dna fidelity and retron genome editing |
WO2023183627A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna |
WO2023183588A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of assessing engineered retron activity, and uses thereof |
WO2024011237A1 (en) | 2022-07-08 | 2024-01-11 | Cornell University | Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease |
WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
WO2024017990A1 (en) | 2022-07-21 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Methods and compositions for treating chronic pain disorders |
WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024079317A1 (en) | 2022-10-14 | 2024-04-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of alpha-synucleinopathies |
Also Published As
Publication number | Publication date |
---|---|
AU8200191A (en) | 1992-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1992001070A1 (en) | High efficiency packaging of mutant adeno-associated virus using amber suppressions | |
JP2655771B2 (en) | Recombinant adeno-associated virus vector | |
US5741683A (en) | In vitro packaging of adeno-associated virus DNA | |
US5688676A (en) | In vitro packaging of adeno-associated virus DNA | |
JP3943048B2 (en) | Method for direct rescue and amplification of integrated virus from cellular DNA of tissue | |
Chiorini et al. | Cloning and characterization of adeno-associated virus type 5 | |
US7238526B2 (en) | Methods and cell line useful for production of recombinant adeno-associated viruses | |
Tratschin et al. | Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function | |
Dubielzig et al. | Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes | |
Samulski | Adeno-associated viral vectors | |
Allen et al. | Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production | |
Chejanovsky et al. | Replication of a human parvovirus nonsense mutant in mammalian cells containing an inducible amber suppressor | |
US5677158A (en) | In vitro packaging of adeno-associated virus DNA | |
JP4108746B2 (en) | AAV production without helper virus | |
JP2005110694A (en) | Generation of high titers of recombinant aav vectors | |
US20040087026A1 (en) | Host cells for packing a recombinant adeno-associated virus (raav), method for the production and use thereof | |
US11926841B2 (en) | AAV-based conditional expression system | |
Park et al. | Scalable production of adeno‐associated virus type 2 vectors via suspension transfection | |
Sollerbrant et al. | A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors | |
Bloom et al. | Construction of pathogenic molecular clones of aleutian mink disease parvovirus that replicate bothin vivoandin vitro | |
Winocour et al. | Modulation of the cellular phenotype by integrated adeno-associated virus | |
Smuda et al. | Adeno-associated viruses having nonsense mutations in the capsid genes: growth in mammalian cells containing an inducible amber suppressor | |
Mendelson et al. | Replication of adeno-associated virus type 2 in human lymphocytic cells and interaction with HIV-1 | |
CN116396983A (en) | Method for detecting AAV antibody titer | |
US5688675A (en) | In vitro packaging of adeno-associated virus DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |